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in the burden of the disease. It has made it possible to provide diagnostic services as 
early as possible, leading to early intervention and ultimately an increase in the quality 
of life of the patients and their families. To address this dearth of genetic data on 
African populations with HL, the research work relevant to and proposed for my PhD 
thesis has been, in part, written and published during my registration for this higher 
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publications”, for most parts of the thesis. The fourth chapter of the thesis will be 
presented in the traditional format and includes an introduction, materials and 
methods, results and discussion sub sections. 
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including Cape Town, Pretoria, Livingstone, Washington DC, Dar Es Salaam and 
Cairo; and lastly (iii) the published works included in this thesis fulfil the 
encouragements put forth by the Faculty of Health Sciences and the University of 
Cape Town (UCT) which seek to disseminate the knowledge generated by scholars 
within the faculty, particularly at PhD level. These publications result in a complete 
body of work that represents a holistic project that effectively enhances the profile of 
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vi 
This thesis is presented with three cohesive elements; (i) sub-Saharan perspective of 
genetic hearing loss; (ii) application of targeted gene panels in resolution of hearing 
loss in sub-Saharan African patients and lastly, (iii) application of whole exome 
sequencing in the resolution of hearing loss in sub-Saharan African patients. 
We have met all requirements and abided by the UCT’s Doctoral Degrees Board, 
under Rules GP6.7 as follows: 
(i) The candidate’s proposal to include publications in the current thesis was approved 
by the UCT Faculty of Health Sciences Doctoral Degrees Board. 
(ii) The thesis contains an adequate Introduction; a chapter on the Aims and 
Objectives; a comprehensive Academic Discussion of the results, forming the basis of 
the Conclusions and Perspectives drawn from this research. 
(iii) Each Results chapter with publications included, is preceded by a synopsis of how 
the publications directly tie to the aims and objectives of the project, as well as to the 
thesis.  
(iv) All included publications, listed below, were written and published during the 
candidate’s tenure as a PhD student. 
List of publications included (all co-authors agreed to the inclusion of these 
manuscripts) 
1. Bosch J, Lebeko K, Nziale JJN, Dandara C, Makubalo N, Wonkam A. 2014. In 
search of genetic markers for nonsyndromic deafness in Africa: a study in 
Cameroonians and Black South Africans with the GJB6 and GJA1 candidate genes. 
OMICS 18: 481–5 
2. Wonkam A, Bosch J, Noubiap JJN, Lebeko K, Makubalo N, Dandara C. 2015. 
No evidence for clinical utility in investigating the connexin genes GJB2, GJB6 and 
GJA1 in non-syndromic hearing loss in black Africans. South African Med. J. 105: 23–
26 
3.  Lebeko K, Bosch J, Nzeale JJ, Dandara C, Wonkam A. 2015. Genetics of 
hearing loss in Africans: use of next generation sequencing is the best way forward. 
Pan Afr. Med. J. 20: 1–14 
vii 
4. Lebeko K, Sloan-Heggen CM, Noubiap JJN, Dandara C, Kolbe DL, Ephraim 
SS, Booth KT, Azaiez H, Santos-Cortez RLP, Leal SM, Smith RJH, Wonkam A. 2016. 
Targeted genomic enrichment and massively parallel sequencing identifies novel 
nonsyndromic hearing impairment pathogenic variants in Cameroonian families. Clin. 
Genet. 90: 288–290 
5. Lebeko K, Manyisa N, Chimusa ER, Mulder N, Dandara C, Wonkam A. 2017. 
A Genomic and Protein–Protein Interaction Analyses of Nonsyndromic Hearing 
Impairment in Cameroon Using Targeted Genomic Enrichment and Massively Parallel 
Sequencing. Omi. A J. Integr. Biol. 21: 90–99. 
 
The candidate, 
Kamogelo Lebeko 
 
  
viii 
Abstract 
 
Hearing Loss (HL) is one of the highest contributors to disability worldwide. The 
highest incidence of the disease is seen in developing countries, such as those in sub-
Saharan Africa (SSA). Patients affected with disabling HL are reported to be more 
than 466 million worldwide. The causes of HL can either be environmental or genetic 
with each contributing about 50% towards all cases, in many settings. In developing 
countries, the environment might contribute more due to poor health services and 
infrastructure available to the population. In the absence of environmental causes, 
there is a genetic component at play, that is largely unknown in African populations. 
Up to 70% of HL of genetic origin are non-syndromic (NS). The mode of inheritance is 
recessive in nearly 77% of non-syndromic HL. Up to date, more than 100 genes have 
been associated with HL harbouring more than 1000 causative variants. In many 
populations of European and Asian descent, pathogenic variants in GJB2 (connexin 
gene 26) and GJB6 (connexin gene 30) are a major contributor to autosomal recessive 
non-syndromic hearing loss (ARNSHL). Comprehensive hearing health care programs 
should cover genetic causes by providing molecular testing, and genetic counselling, 
specifically SSA where genes and mutations causing HL remain largely unknown.  
 
The aim of this project was thus to uncover the genetic causes of HL among patients’ 
cohorts from Cameroon and South Africa. This was addressed by 1) sequencing 
common variants in the most relevant genes in other populations (GJB2 and GJB6), 
2) using a targeted gene panel to resolve HL in 10 multiplex families from Cameroon 
presenting with ARNSHL and negative for GJB2 and GJB6 mutations screening, 3) 
screening novel variants found in known genes in a cohort of 82 singleplex HL cases 
from Cameroon and South Africa, and lastly, 4) using Whole Exome sequencing to 
explore the  two unresolved multiplex cases with and subsequent findings confirmed 
by functional studies, and also screened in 80 singleplex HL cases.  
 
The following findings are reported: 
 
ix 
GJB6, GJA1 mutations screening and literature review 
No GJA1 or GJB6 mutation was not found in multiplex and simplex cases of HL in both 
Cameroonians and South Africans. The review of the literature confirms that the 
prevalence of GJB2- or GJB6-related NSHL is approximating to zero in most sub-
Saharan African populations. 
Targeted Exome Sequencing (OtoSCOPE) 
The targeted genes, panel that included 116 genes, was able to resolve 7 of 9 families 
(77.8%) which were successfully sequenced, with one family failing to be sequenced. 
The causative variants identified in the 7 resolved families were : 1) compound 
heterozygous c.5806_5808delCTC and c.5880_5882delCTT in MYO7A; 2) compound 
heterozygous c.646T>A (p.Phe216Ile) and c.38G>A (p.Arg13His) in LOXHD1; 3) 
homozygous c.766-2A>G in OTOF; 4) a deletion and a complex copy number variation 
in STRC; 5) compound heterozygous c.1678G>A (p.Asp560Asn) and 
c.2007C>A(p.Asp669Glu) in SLC26A4; 6) Homozygous c.1996C>T(p.Arg666Stop) in 
MYO7A; 7) compound heterozygous c.6399C>A(p.Asp2133Glu) and c.2000T>C 
(p.Met667Thr) in CDH23. Five out of 12 variants were novel. Screening of these 
causative variants in known genes, in 82 singleplex HL cases from Cameroon and 
South Africa was unable to resolve any of the cases: the variants were in either 
heterozygous in low frequency or absent. 
Bioinformatic pathways exploration of SNP data of known HL genes revealed an 
extensive network within the HL genes, with 10 identified as important nodes, including 
MYO7A. Most HL genes were found to be involved in two biological processes which 
were sensory perception of mechanical stimulus (GO: 0050954, p= 1.430e-8) and 
sound (GO: 0007605, p = 1.246e-8). The molecular functions of variants found within 
these genes were found to mostly fall within the binding (GO: 0005488) and/or 
structural molecule activity (GO: 0005198). 
Whole Exome sequencing  
Whole exome sequencing was performed on four of the nine multiplex families: the 
two families that were unresolved by targeted panel sequencing, and two previously 
resolved families that were used as positive controls for the variant annotation and 
filtering pipeline. The results were the resolution of 3/4 families, including the two-
x 
positive control. The previously unresolved “family 8” was found to harbour a novel 
variant within the GRXCR2 gene, a gene only associated with HL once before. The 
c.251delC variant was revealed through in silico studies to cause a premature stop 
codon at position 116 due to its frameshift effect. The screening of this variant in our 
cohort of 80 singleplex cases revealed one other unrelated HL patient harbouring this 
causative variant. Due to the limited literature on the gene and its protein, in silico 
studies were used to show the predicted secondary structure folding of the protein as 
well as potential protein binding regions. Analysis showed that the predicted loss of a 
stable region of the protein as well as that of a putative binding domain could explain 
the pathogenic nature of the variant. In vitro studies showed that the variant hindered 
the detection of the protein by way of a DDK tag downstream in the plasmid. 
Additionally, GFP-Tagged GRXCR2 showed altered expression pattern in the variant 
when compared to the wildtype.  
 
In summary, our data has revealed the efficacy of using next generation sequencing 
tools in resolving HL among sub-Saharan African patients as opposed to the single 
candidate gene approach. In our quest, we have employed two widely used strategies, 
targeted panel and whole exome sequencing (WES), both of which have had great 
successes in various populations. The targeted approach was able to resolve 77.8% 
of our families but did not detect variants for two of the families revealing the presence 
of other variants harboured in rarely associated gene not captured or included on the 
panel. This prompted for the use of a more comprehensive approach such as WES. 
These results corroborated with those of two families previously resolved by targeted 
exome sequencing. Additionally, one of the previously unresolved family was now 
resolved. This showed that WES was sensitive enough to detect variants in known HL 
genes but comprehensive enough to detect variants in other regions of the exome 
which have not been associated with HL or rarely associated with HL. The benefit of 
WES also extends to the contribution of exomic data from patients of African descent 
as there is an underrepresentation of this group in exome repositories as well as 
genomic or SNP databases. To the best of our knowledge, this is the first study to use 
WES to resolve HL in patients of African descent. The other benefit of such a venture 
is the use of this data not only for patients in SSA but also those in the diaspora. 
xi 
 
In conclusion, we have successfully demonstrated the feasibility of using NGS tools in 
identifying causative variants in HL patients in SSA. Additionally, we have shown that 
WES is a more suitable approach to trying to resolve HL in Africa. Therefore, the data 
strongly support that genetic studies on families segregating HL in SSA could be the 
next frontier of HL genetic research, of global importance through discovering novel 
variants in known genes, and potentially novel genes. These studies will improve HL 
genetic diagnosis, retrospective counselling and testing, prevention and care including 
future prediction of treatment outcomes in sub-Saharan Africans, and in people of 
African descent. 
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Chapter 1: Introduction 
 
Hearing Loss (HL) is the number one communication disorder in the world. It is defined 
by the WHO as the inability to detect sound greater than 25dB in the better hearing 
ear of adults and 30dB in the better hearing ear of children (World Health Organisation, 
2012). The incidence rate of congenital HL is about 0.5-1/1000 live births in developed 
countries and is as high as 7/1000 live births in developing countries (Olusanya and 
Newton, 2007). The disparities seen is thought to be due to the high burden of 
environmental factors which plague developing countries due to poor health services 
and lack of resources and infrastructure (Olusanya and Newton, 2007). Generally, 
these factors contribute to 50% of HL cases with the remainder being genetic. Due to 
the high burden of environmental factors in developing countries and lower resources, 
these figures have not been observed, and many cases remain classified as cases of 
unknown origin.  
Hearing loss is highly heterogeneous in both its manifestation and its heritability. The 
most common manifestation of the disease is HL on its own and is referred to as 
nonsyndromic (NSHL). This happens in about 70% of all HL cases. Syndromic HL 
accounts for up to 30% of cases observed where the HL is accompanied by another 
ailment. Such syndromes included Usher Syndrome, Pendred syndrome and 
Waardenburg syndrome just to mention a few. Of the NSHL cases, the mode of 
inheritance can be autosomal, or sex linked, dominant or recessive as well as 
mitochondrial. The most common mode of inheritance is autosomal recessive 
nonsyndromic hearing loss (ARNSHL) which accounts for upwards of 80% of all 
genetic cases.  
The genetic causes of HL have been uncovered across various populations. The 
connexin gene GJB2 is by far the most frequently associated gene with ARNSHL. It 
accounts for up to 50% of HL cases among patients of European descent, particularly 
the c.35delG variant (Tsukada et al., 2015). However this variant has been shown to 
be founder variant and is not present in patients of different ethnicities (Tsukada et al., 
2015). Nonetheless, screening of this gene has been extensive in different populations 
and has seen the identification of population specific variants for the Asian 
(Dzhemileva et al., 2010), Jewish and Ghanaian (Hamelmann et al., 2001) population 
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groups. Outside of these above mentioned groups and their region/group specific 
founder variants, the gene does not seem to play a significant role, particularly in sub-
Saharan African populations (Gasmelseed et al., 2004; Kabahuma et al., 2011; Bosch 
et al., 2014a). This has been demonstrated several times over.  
Initial efforts to uncover causative genes and their variants was done through 
homozygosity mapping and direct Sanger sequencing. This led to the identification of 
more than 80 genes in over 100 loci (Van Camp and Smith, 2017). These genes 
harboured more than 1000 variants associated with HL. This was performed on 
populations from Asia, Europe, the Americas and the Middle East, but did not included 
sub-Saharan African populations (Rudman et al., 2017). In order to facilitate the 
identification of causative genes and their variants specific to the sub-Saharan region 
as well as contribute new knowledge to the field, a more rapid approach is needed 
(Lebeko et al., 2015). One that would see a large amount of data being generated and 
made available to patients of this region. 
Given the genetic heterogeneity of the disease, next generation sequencing (NGS) 
tools are best suited to be utilized in the effort of trying to resolve HL in the sub-
Saharan African region. These tools allow for multiple parallel enrichment and 
sequencing of specific regions of the genome. These can be targeted to genes known 
to contribute to HL as uncovered in other population groups. The benefit of this 
approach is that there is a shorter route when it comes to filtering of results and their 
analysis as all the genes are known to cause HL and thus their variants are potentially 
pathogenic and causative in nature. There is also often no need to have added 
evidence towards the annotation of identified variants as the genes have been 
validated as causative. Several panels have been developed which capture coding 
regions of genes which have already been associated with HL. These include 
OtoSCOPE (Shearer et al., 2010), MiamiOtoGenes (Tekin et al., 2016), and OtoSeq 
(Shahzad et al., 2013; Sivakumaran et al., 2013) to name a few which are available 
for use to screen between 116-248 known HL genes.  
Alternatively, given the Mendelian nature of the disease, whole exome sequencing 
(WES) is available and suitable to explore a wider region of the genome (Teer and 
Mullikin, 2010). It is still only 1% of the genome and is thus manageable in terms of 
data analysis. One would need a lot more phenotypic information when applying a 
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filtering strategy as to allow for accurate selection of potentially pathogenic variants. 
This includes mode of inheritance as well as the exclusion of other ailments to rule out 
SHL. With the above-mentioned tools available, it is thus feasible to start the journey 
to identifying which genes contribute to HL in this vast, diverse region of Sub-Saharan 
Africa. 
1.2. Aim: 
The overall aims of this project were:  
(i) To investigate the most prevalent genes associated with ARNSHL in a 
cohort of HL patients from Cameroon and South Africa.  
(ii) To investigate the utility of one of the available targeted gene enrichment 
panels (OtoSCOPE) in resolving multiplex cases of ARNSHL and 
uncovering a common variant which is contributing towards the disease.  
(iii) To investigate the efficacy of using a wider approach such as WES in 
resolving multiplex cases from Cameroon and discovering new genes and 
their variant(s) which are contributing towards the disease in the region. 
 
1.3. Objectives 
The aims were carried out through the following objectives: 
a) Recruitment of multiplex and singleplex cases from Cameroon and South Africa 
with putatively genetic causes of ARNSHL.  
b) Screening of the most common genes (GJB2, GJB6 and GJA1) in this cohort. 
c) Selection of multiplex families for resolution through OtoSCOPE. 
d) Exploration of HL gene annotation and network of genes included on 
OtoSCOPE 
e) Screening of identified variants in simplex cases. 
f) Selection of multiplex families for resolution through whole exome sequencing 
g) Screening of WES uncovered variants in the cohort of singleplex cases 
h) Bioinformatics analysis of newly uncovered genes and variants 
i) Functional studies to explore and validate pathogenicity of variants 
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Chapter 2: GJB6, GJA1 mutations screening and literature reviews 
 
Synopsis: The chapter presents three published articles: an original research which 
explored the most commonly associated genes in sub-Saharan Africa and two peer- 
reviewed review articles on the advocacy of using next generation sequencing 
technologies in resolving hearing loss among patients of African descent. 
 
2.1. Bosch J, Lebeko K, Nziale JJN, Dandara C, Makubalo N, Wonkam A. 2014. In 
search of genetic markers for nonsyndromic deafness in Africa: a study in 
Cameroonians and Black South Africans with the GJB6 and GJA1 candidate genes. 
OMICS 18: 481–5. 
 
Abstract 
Deafness is the most common sensory disability in the world and has a variety of 
causes. Globally, variants in GJB2 have been shown to play a major role in 
nonsyndromic deafness, but this has not been seen in Africans. Two other connexin 
genes, GJB6 and GJA1, have been implicated in hearing loss but have seldom been 
investigated in African populations. We set out to investigate the role of genetic 
variation in GJB6 and GJA1 in a group of Cameroonian and South African Blacks with 
nonsyndromic recessive hearing loss. A subset of 100 patients, affected with 
nonsyndromic hearing loss, from a cohort that was previously shown not to have GJB2 
variant, was analysed by Sanger sequencing of the entire coding regions of GJB6 and 
GJA1. In addition, the large-scale GJB6-D3S1830 deletion was also investigated. No 
pathogenic variant was detected in either GJB6 or GJA1, nor was the GJB6-D3S1830 
deletion detected. There were no statistically significant differences in sequence 
variants between patients and controls. Variants in GJB6 and GJA1 are not a major 
cause of nonsyndromic deafness in this group of Africans from Cameroon and South 
Africa. Currently, there is no sufficient evidence to support their testing in a clinical 
setting for individuals of African ancestry.  
 
Nature of Publication: Original Full Journal Article  
5 
Journal/Publisher: OMICS, Journal of Integrative Biology, Mary Anne Liebert Inc.; Peer 
reviewed; Online ISSN: 1557-8100 
Candidate contribution: Performed experiments pertaining to GJB6 and analysis of 
the results. Contributed to writing in part with relation to GJB6 analysis 
Co-Authors contributions: 
JB: Conceived and designed experiments for the project, performed the experiments 
and analysed data, wrote and revised the manuscript. 
JJNN: Performed the recruitment of patients,  
NM: Performed the recruitment of patients 
CD: Contributed reagents and materials for the experiments, revised manuscript 
AW: Conceived and designed the experiments, analysed data, wrote and revised and 
approved manuscript. 
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2.2.: Wonkam A, Bosch J, Noubiap JJN, Lebeko K, Makubalo N, Dandara C. 2015. 
No evidence for clinical utility in investigating the connexin genes GJB2, GJB6 and 
GJA1 in non-syndromic hearing loss in black Africans. South African Med. J. 105: 23–
26. 
 
Abstract:  
Background. Deafness is the most common sensory disability in the world. Globally, 
variants in GJB2 (connexin 26) have been shown to play a major role in non-syndromic 
deafness. Two other connexin genes, GJB6 (connexin 30) and GJA1 (connexin 43), 
have been implicated in hearing loss, but these genes have seldom been investigated 
in black Africans. We aimed to validate the utility of testing for GJB2, GJB6 and GJA1 
in an African context. Methods. Two hundred and five patients with non-syndromic 
deafness from Cameroon and South Africa had the full coding regions of GJB2 
sequenced. Subsequently, a carefully selected subset of 100 patients was further 
sequenced for GJB6 and GJA1 using Sanger cycle sequencing. In addition, the large-
scale GJB6-D3S1830 deletion was investigated. Results. No pathogenic variants that 
could explain the hearing loss were detected in GJB2, GJB6 or GJA1, and the GJB6-
D3S1830 deletion was not detected. There were no statistically significant differences 
in genomic variations in these genes between patients and controls. A comprehensive 
literature review supported these findings. Conclusion. Variants in GJB2, GJB6 and 
GJA1 are not a major cause of non-syndromic deafness in black Africans and should 
not be investigated routinely in clinical practice. 
 
Nature of Publication: Review Article  
Journal/Publisher: South African Medical Journal; Health and Medical Publishing 
Group; ISSN: 0256-9574 
Candidate contribution: Performed experiments pertaining to GJB6 and analysis of 
the results. Contributed to writing in part with relation to GJB6 analysis 
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2.3. Lebeko K, Bosch J, Nzeale JJ, Dandara C, Wonkam A. 2015. Genetics of hearing 
loss in Africans: use of next generation sequencing is the best way forward. Pan Afr. 
Med. J. 20: 1–14. 
 
Abstract: 
Hearing loss is the most common communication disorder affecting about 1-7/1000 
births worldwide. The most affected areas are developing countries due to extensively 
poor health care systems. Environmental causes contribute to 50-70% of cases, 
specifically meningitis in sub-Saharan Africa. The other 30-50% is attributed to genetic 
factors. Nonsyndromic hearing loss is the most common form of hearing loss 
accounting for up to 70% of cases. The most common mode of inheritance is 
autosomal recessive. The most prevalent variants associated with autosomal 
recessive nonsyndromic hearing loss (ARNSHL) are found within connexin genes 
such as GJB2, mostly in people of European and Asian origin. For example, the 
c.35delG variant of GJB2 is found in 70% of ARNSHL patients of European descent 
and is rare in populations of other ethnicities. Other GJB2 variants have been reported 
in various populations. The second most common variants are found in the connexin 
gene, GJB6, also with a high prevalence in patients of European descent. To date 
more than 60 genes have been associated with ARNSHL. We previously showed that 
variants in GJB2, GJB6 and GJA1 are not significant causes of ARNSHL inpatients 
from African descents, i.e. Cameroonians and South Africans. In order to resolve 
ARNSHL amongst sub-Saharan African patients, additional genes would need to be 
explored. Currently at least 60 genes are thought to play a role in ARNSHL thus the 
current approach using Sanger sequencing would not be appropriate as it would be 
expensive and time consuming. Next Generation sequencing (NGS) provides the best 
alternative approach. In this review, we reported on the success of using NGS as 
observed in various populations and advocate for the use of NGS to resolve cases of 
ARNSHL in sub-Saharan African populations. 
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Chapter 3: Application of targeted exome sequencing in ARNSHL in 
Sub-Saharan African patient 
 
Synopsis: In order to timeously identify the causative variants which contribute to HL 
in sub-Saharan African patients, NGS tools should be employed. This chapter includes 
two original publications that: 1) Report on the findings of using a comprehensive HL 
panel called OtoSCOPE to resolve HL in 10 selected multiplex families, and 2) The 
prevalence of identified variants in a cohort of singleplex cases as well as the 
bioinformatics network profile of HL genes. 
 
3.1: Lebeko K, Sloan-Heggen CM, Noubiap JJN, Dandara C, Kolbe DL, Ephraim SS, 
Booth KT, Azaiez H, Santos-Cortez RLP, Leal SM, Smith RJH, Wonkam A. 2016. 
Targeted genomic enrichment and massively parallel sequencing identifies novel 
nonsyndromic hearing impairment pathogenic variants in Cameroonian families. Clin. 
Genet. 90: 288–290. 
 
Abstract 
This article explored the use of a targeted gene enrichment panel called OtoSCOPE 
in the resolution of 10 selected multiplex families from Cameroon presenting with 
ARNSHL. The resolution rate after screening 66 known HL genes was 77%. Twelve 
different variants (5 of which were novel) were identified in 6 different genes, majority 
of which contributed to the disease as a result of compound heterozygotes. The 
identified variants were not significantly present in a cohort of 80 Singleplex cases and 
thus they remain unresolved. The unresolved multiplex cases highlight that there are 
other genes which contribute to HL which can still be identified as significant 
contributors to the disease for this cohort. 
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3.2. Lebeko K, Manyisa N, Chimusa ER, Mulder N, Dandara C, Wonkam A. 2017. A 
Genomic and Protein–Protein Interaction Analyses of Nonsyndromic Hearing 
Impairment in Cameroon Using Targeted Genomic Enrichment and Massively Parallel 
Sequencing. Omi. A J. Integr. Biol. 21: 90–99. 
 
Abstract 
 
Hearing impairment (HI) is one of the leading causes of disability in the world, 
impacting the social, economic, and psychological well-being of the affected individual. 
This is particularly true in sub-Saharan Africa, which carries one of the highest burdens 
of this condition. Despite this, there are limited data on the most prevalent genes or 
variants that cause HI among sub-Saharan Africans. Next-generation technologies, 
such as targeted genomic enrichment and massively parallel sequencing, offer new 
promise in this context. This study reports, for the first time to the best of our 
knowledge, on the prevalence of novel variants identified through a platform of 116 HI 
genes (OtoSCOPE), among 82 African probands with HI. Only variants OTOF 
NM_194248.2:c.766-2A>G and MYO7A NM_000260.3:c.1996C>T, p.Arg666Stop 
were found in 3 (3.7%) and 5 (6.1%) patients, respectively. In addition, and uniquely, 
the analysis of protein–protein interactions (PPI), through interrogation of gene 
subnetworks, using a custom script and two databases (Enrichr and PANTHER), and 
an algorithm in the igraph package of R, identified the enrichment of sensory 
perception and mechanical stimulus biological processes, and the most significant 
molecular functions of these variants pertained to binding or structural activity. 
Furthermore, 10 genes (MYO7A, MYO6, KCTD3, NUMA1, MYH9, KCNQ1, UBC, 
DIAPH1, PSMC2, and RDX) were identified as significant hubs within the 
subnetworks. Results reveal that the novel variants identified among familial cases of 
HI in Cameroon are not common, and PPI analysis has highlighted the role of 10 
genes, potentially important in understanding HI genomics among Africans. 
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Chapter 4: Whole exome sequencing reveals novel frameshift mutation 
in GRXCR2 that alters protein expression and localisation in a multiplex 
family from Cameroon 
 
Introduction 
Hearing Loss (HL) is one of the most common sensroy disorders that  affects both the 
elderly and young alike (Atik et al., 2015). With congenital cases of HL, it can be a 
shock to families, particularly when there is no family history of HL. Factors resulting 
in congenital HL can be environmental or genetic or result from an interaction of the 
two. In sub-Saharan Africa (SSA), the contribution of the environment to HL is much 
higher than known genetic contributors. As a result, cases which have no known 
envirnomntal cause are classified as unknown. This differs greatly to developed 
countries where the identification of prevalent genes and their variants has allowed for 
the development of specific gene panels used in diagnostic services. These 
developments have been made possible by decades of single gene discovery within 
these population groups, but similar progress has been lacking in SSA. These panels 
may still be of relevance in unexplored population groups such as sub-saharan African 
populations as they offer a great starting point with the screening of known genes 
associated with HL. This is a far more cost effective approach than the traditional 
single candidate gene approach. However, the use of these panels has proven to be 
less effective in resolving patients of African descent (Shearer et al., 2014b; Yan et 
al., 2016). Previously we used OtoSCOPE®, a targeted gene enrichment (TGE) panel, 
to try and resolve cases of autosomal recessive nonsyndromic hearing loss (ARNSHL) 
from 10 multiplex families from Cameroon, of which 7 families (77.8%) were 
successfully resolved (Lebeko et al., 2016). This is a relatively high resolution rate 
compared to other literature where TGE was employed to resolved cases of ARNSHL 
in patients of sub-Saharan descent (Manzoli et al., 2013; Shearer et al., 2014b; 
Rudman et al., 2017), probably owing to the stringent inclusion criteria of only familial 
HL cases. These lower resolution rates among Africans in several studies (Shearer et 
al., 2014b; Yan et al., 2016), as well as the presence of at least two unresolved families 
in our previous study (Lebeko et al., 2016) suggests the presence of causative variants 
in novel genes which were not investigated through OtoSCOPE® and other TGE 
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platforms. It is evident that a wider approach is needed to elucidate the cause of HL in 
these unresolved families.  
Whole exome sequencing (WES) provides a suitable strategy that allows for the 
interrogation of a select part of the human genome. The gene enrichment process 
captures the exons, which are protein coding regions that make up to 1% of the human 
genome, the 5’- and 3’-UTRs, which affect gene translation process and can affect 
gene functionality, and splice regions found within specific regions of introns. This all 
allows for a comprehensive coverage which can detect genetic variations that 
potentially alter the translation of the gene as well as the integrity of the gene product. 
With congenital HL mostly being of genetic aetiology and largely a monogenic 
Mendelian disorder, WES is appropriate to investigate specifically familial cases. This 
approach has been employed in various populations and has demonstrated its 
suitability in uncovering novel causative variants in genes previously associated with 
HL as well as in genes rarely or not yet associated with HL (Atik et al., 2015; Liu et al., 
2015; Pandey and Pandey, 2015; Сhurbanov et al., 2016; Rudman et al., 2017). In 
the present study WES was therefore employed to identify the causative variants 
harboured in the unresolved multiplex families previously sequenced with 
OtoSCOPE® (Lebeko et al., 2016). Additionally, to show the sensitivity and accuracy 
of WES in detecting causative variants, we also sequenced two multiplex families 
which had previously been resolved through OtoSCOPE®.  
 
Methodology 
Ethical approval  
The study was performed in accordance with the Declaration of Helsinki. This study 
was granted ethics approval by the Cameroon National Ethics Committee (ethics 
approval N°123/CNE/SE/2010 and N°033/CNE/DNM/07) as well as the university of 
Cape Town Human Research Ethics Committee (ethics approval HREC REF: 
455/2014 and HREC REF: 132/2010). Written informed consent was obtained from 
patients 18 years or older or from parents/guardians for minors with (Wonkam et al., 
2013; Bosch et al., 2014a,b) verbal assent from the children. 
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Patients’ Clinical Data 
Participants were recruited in Cameroon and South Africa as previously reported 
(Wonkam et al., 2013; Bosch et al., 2014b). In Cameroon, patients were recruited at 
various outpatient clinics in different regions of the country. In South Africa, self-
identified black Xhosa participants were recruited at the Efata School of the deaf and 
Blind in Mthata, Eastern Cape (Bosch et al., 2014a). Patients were included in this 
study if they were of Black African descent presenting with ARNSHL of either 
putatively genetic origin or of unknown cause. Patients were excluded from this study 
if there was indication of an environmental cause or evidence of syndromic HL (Bosch 
et al., 2014a). As previously reported, clinical evaluation confirmed diagnosis of 
sensorineural HL according to current clinical standards alongside collection of 
qualitative data (including family history) through a comprehensive questionnaire 
(Wonkam et al., 2013). Syndromic HL was ruled out after examination by an 
ophthalmologist and a medical geneticist. All participants have been evaluated for 
causative variants in GJB2, GJB6 and GJA1.  
 
Familial Cases evaluated through Next Generation Sequencing 
Four multiplex families from the cohort were selected for WES. Their recruitment was 
conducted as described above. Families included had at least 2 affected HL probands 
of the same generation with unaffected parents (Lebeko et al., 2016).  
 
Control Population 
Ethnically matched control samples were used in this study. They were 100 normal 
hearing patients from different regions of Cameroon, recruited at the same centres as 
the patients. Controls for the South African Population were taken from Black South 
African participants’ DNA available to the Division of Human Genetics. 
 
Whole Exome Sequencing 
Four multiplex families were selected for WES, two of which had been previously 
resolved through OtoSCOPE® (Lebeko et al., 2016). DNA was extracted from blood 
samples as previously reported (Bosch et al., 2014b). Using the SureSelect Human 
All Exon 50 Mb kit (Agilent Technologies, Inc.), which covers the exonic sequences of 
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≈24 000 genes corresponding to 50 Mb of genomic DNA, library preparation and 
sequencing on the Illumina HiSeq 2000 were performed at the Institute of Human 
Genetics, Helmholtz Zentrum München, Germany. The Burrows-Wheeler Alignment 
tool (version 0.7.5) was used to align the reads to the human genome assembly hg19 
(GRCh37). Variant calling was performed with SAMtools (v0.1.19) and PINDEL 
(v0.2.4t). Variant quality was determined using the SAMtools varFilter script: default 
parameters were applied, with the exception of the minimum P value for base quality 
bias (−2), which was set to 1e−400. Variant annotation was performed applying 
custom Perl scripts, including information about known transcripts (UCSC genes and 
RefSeq genes), known variants (dbSNP v135), type of variant, and amino acid change 
(where applicable). Variants were filtered and excluded if there was no AF information 
in DBSNP137, 1000KG201204, ESP6500AA, ESP6500EA databases. Coding and 
splicing variants were included, and potential genes and variants were searched 
through a PubMed search using the following terms: “deaf, deafness, sloping + 
audiograms, prelingual + sensorineural + profound, prelingual + sensorineural + 
symmetric.” 
 
In Silico pathogenicity prediction of genomic variants 
GRXCR2 cDNA sequence was extracted from the Ensemble genome browser 
(ENST00000377976.2) and manually edited by deleting the cytosine at position 251 
of the cDNA sequence. The altered sequence was then interrogated using two online 
programs, namely ExPASy (web.expasy.org/translate/) and EMBOSS Transeq 
(http://www.ebi.ac.uk/Tools/st/emboss_transeq/). This was done to predict the effect 
of the identified novel frameshift deletion on the translated protein sequence. To infer 
the importance of this variant across species, a multiple sequence alignment of higher 
primates was extracted from Ensemble (http://ensembl.org). 
 
Protein Prediction and Modelling 
PSIPRED protein sequence analysis workbench online platform (Buchan et al., 2013) 
(http://bioinf.cs.ucl.ac.uk/psipred/) was used to determine the secondary structure of 
the translated protein sequence of GRXCR2. The platform has a variety of tools and 
algorithms which can be applied to the provided sequence. The PSIPREDv3.3 tool, 
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which predicts the secondary structures of the protein sequence inputted, and 
DISOPRED 3, which predicts intrinsically disordered regions (IDRs) and protein 
binding sites within them (i.e. IDRs), were selected to analyse the sequence. Protein-
protein interactions and potential network of GRXCR2 was investigated using STRING 
(https://string-db.org/). 
 
Genotyping of patients’ samples  
To investigate any potentially causative and secondary variants harboured in this 
gene, the entire coding region of GRXCR2 was screened using direct Sanger 
sequencing in 80 patients and 100 controls. Primers (Appendix Table A1) were 
designed to amplify all three exons of GRXCR2. To amplify the desired fragments, 
PCR was performed by denaturing at 95°C for 3 minutes followed by 35 cycles of 30 
second denaturation at 94°C, 30 second primer annealing at 55°C and 1 minute 
elongation at 72°C. This was followed by a final elongation step at 72°C for 10 minutes. 
PCR amplification was confirmed by gel electrophoresis and products were cleaned 
up using FastAp and Endonuclease I. BigDye® Terminator v3.1 Cycle Sequencing 
mix (Life Technologies) was used for the sequencing reaction according to the 
manufacturer’s guidelines. Sequencing products were resolved on 3130xl Genetic 
Analyser ABI Prism (Applied Biosystems) using capillary electrophoresis and resultant 
electropherograms were analysed using DNAStar software. 
 
Functional analysis of the GRXCR2 Variant 
Plasmid DNA construct Isolation and amplification 
GRXCR2 open reading frame (ORF) cloned into a pCMVEntry vector was purchased 
from Origene Technologies (Cat no: RC213752). Within this vector, the GRXCR2 ORF 
contained a DDK-tag and myc-tag at the C-terminus end. (Appendix Figure 4 A1). Site 
directed mutagenesis (SDM) was performed in order to introduce the identified 
c.251delC variant within this construct. Custom designed SDM primers [Forward 5`-
ACTGCTCAGAGATCAGTGTGTTTAGAGAGGG-3` and Reverse -5`-
CCCTCTCTAAACACACTGATCTCTGAGCAGT-3`] incorporating the variant were 
produced (Whitehead Scientific) and used in PCR using the pCMV-GRXCR2 vector 
as template and the KAPA HiFi HotStart ReadyMix PCR Kit (Roche). The PCR 
reaction mix was prepared as a 50uL reaction according to the manufacturers 
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guidelines (Appendix). The PCR amplification was confirmed by resolving 10ul on a 
1% agarose gel. The methylated parental plasmid which would not have the variant 
was digested by 1uL Dpn1 enzyme at 37°C for 1 hour. Confirmation of the presence 
of plasmid after digestion was again confirmed on a 1% agarose gel through 
electrophoresis. The plasmid was then inserted into competent XL1-Blue bacterial 
cells through transformation using the heat shock method. After 2hr incubation, 100 
µL of bacterial culture was spread onto LB-Agar plates with a 50ug/ul concentration of 
kanamycin and incubated at 37°C O/N. Colonies on the plates indicated successful 
transformation. Plasmid DNA was harvested from O/N cultures grown in 5ml Luria 
Broth with 50ug/ul Kanamycin using the PureYield™ Plasmid Miniprep System 
(Promega) and integrity of the plasmid DNA was confirmed after resolution on a 1% 
agarose gel.  
 
PCR primers [Forward GFP-HindIII: 5’-GCCGCCAAGCTTCCATGGAGG-3’ and 
Reverse GFP-BamHI: 5’-CCGCGTGGATCCTTGATTGCA-3’] were then designed to 
amplify the wildtype and mutated ORFs with the introduction of the restriction enzyme 
site for HindIII at the 5’ end and BamHI at the 3’ end. This was done to allow for sub 
cloning of the ORFs into the selected pEGFP-C1 vector (Appendix Figure A2). This 
GFP expression vector allows for the cloning of the GRXCR2 ORF such that the 
resulting recombinant GFP-GRXCR2 fusion protein is expressed with the GFP tagged 
on the N-terminal side of GRXCR2. PCR amplification was performed as outlined and 
resolved on a 1% agarose gel. After successful amplification was observed, the PCR 
products were cloned into a pGEM®-T Easy vector (Promega) (Appendix Figure A3) 
using the T4 DNA ligase (Promega). This vector has T-overhangs which will bind to 
the A-overhangs left by Taq Polymerase during PCR and thus allows for cloning of 
PCR products. Following incubation O/N at 4°C, the ligation mixture was transformed 
into competent DH5α bacterial cells and plating onto agar plates with 100ug/uL 
ampicillin and an O/N incubation at 37°C. Positive colonies were confirmed using 
colony PCR followed by resolution on agarose, using the primers described earlier. A 
single positive colony per reaction was picked and inoculated in 5ml Luria Broth with 
100ug/uL ampicillin O/N at grown at 37°C on a shaker. Plasmid DNA was isolated 
using the GenElute™ Plasmid Miniprep Kit (SigmaAldrich) and integrity of the plasmid 
DNA was observed after resolution through electrophoresis on a 1% agarose gel. 
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Following confirmation of successful ligation of the ORFs into the pGEM-T easy vector, 
double restriction enzyme (RE) digestion using BamHI (Promega) and HindIII 
(Promega) was performed on the recombinant pGEM T-GRXCR2WT and pGEM T-
GRXCR2MT and the peGFP-C1 vector. To verify the success of the digestion by the 
REs, PCR products were resolved on a 1% agarose gel. The digested ORFs were 
extracted from the gel using the QIAquick Gel Extraction Kit (Qiagen) according to the 
manufacturer’s guideline. pEGFP-C1 was cleaned up after digestion using GeneJET 
PCR Purification Kit (ThermoFischer) following the manufacturer’s guidelines.  
Ligation reactions were set up to ligate the digested ORF fragments into the digested 
pEGFP-C1 vector using T4 DNA ligase (Promega). Following O/N incubation at 4℃, 
ligation reactions were transformed into competent DH5α bacterial cells. Transformed 
cells were plated onto agar with 50ug/ul kanamycin and incubated O/N at 37°C. 
Positive colonies were confirmed using colony PCR and primers that allows for 
amplification of the cloned ORFs. Agarose gel electrophoresis confirmed the presence 
of the ORFs and thus success of ligation into the pEGFP-C1 vector. A single positive 
colony per reaction was picked and inoculated in 5ml Luria Broth with 50ug/uL 
kanamycin O/N at 37°C on a shaker. Plasmid DNA was harvested using the 
PureYield™ Plasmid Miniprep System (Promega) and integrity of the plasmid DNA 
was observed after resolution through electrophoresis on a 1% agarose gel. Cloning 
was further confirmed through direct sanger sequencing.  
 
Expression and Detection of Ha-tagged GRXCR2 in HEK293 cells 
Cell line selection 
In an effort to model the behaviour of proteins expressed in stereocilia of the inner ear 
hair cells, researchers have turned to using cell lines that present with an apical border 
or a brush border (Loomis et al., 2003). These are cell lines that present with finger-
like projections such as microvilli at their periphery or on their cellular membrane 
(Loomis et al., 2003). The similarities in cellular structure and architecture allow for 
inference to be made with regards to the behaviour of the proteins in the inner hair 
cells which play a role in stereocilia formation and maintenance. This is important for 
proteins thought to be involved in the structure of the cilia or their development as is 
postulated with GRXCR2. Human Embryonic Kidney (HEK) 293 is a widely used cell 
line across various disciplines and topics. It is generally easy to maintain in tissue 
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culture and to transfect using conventional techniques. It was selected for this study 
due to its apical structures and cellular architecture as well as its relative ease of 
growth and transfection. Cells were grown from passage number 14 in Dulbecco's 
Modified Eagle's medium [DMEM] (Sigma-Aldrich) supplemented with 10% Foetal 
Bovine Serum [FBS] (Gibco, Thermo Fisher) and 1% Penicillin Streptomycin (Pen 
Strep) (Gibco, Thermo Fisher) and incubated at 37°C in a humidified incubator with 
5% CO2. 
 
Transfection, protein isolation and Western Blotting  
HEK293 cells were counted and 3.5 x 104 cells were plated per well in 6 well plates 
and grown until 50-60% confluent under the conditions described above. In order to 
introduce plasmid DNA into HEK293 cells, 1 ug of pCMV-GRXCR2WT or pCMV-
GRXCR2MT was added to 100ul of complete medium as well as 3ul of X-
tremeGENE™ HP DNA Transfection Reagent (Roche) and incubated at room 
temperature for 20 minutes. This was then added to the plated cells and gently agitated 
to allow even distribution of the reaction mix. This was further incubated for 30 hours 
at 37°C in a humidified incubator with 5% CO2.  
Following a 30-hour incubation period post-transfection, total protein was harvested 
from the cells using boiling blue buffer (Appendix). PBS (Appendix) was used to wash 
cells twice after medium had been removed. Fifty microliters (50ul) of boiling blue 
buffer was added onto the cells and the cells scrapped using the plunger of a 1 ml 
syringe.  If consistency of the extract was too thick, more boiling blue buffer was added 
(up to 150ul total) in order to achieve maximal cell lysis. The extract was then 
transferred to a 1.5ml sterile microtube and boiled at 95°C for 15min in a heating block. 
The lysate was stored at -20°C until use.  
For total protein resolution on SDS-PAGE, a 1 mm thick 12% resolving gel (Appendix) 
and a 5% stacking gel (Appendix) were prepared in a Bio-Rad Mini PROTEAN© 3 
casting apparatus as per the manufacturer’s instructions (Bio-Rad). The prepared gel 
was placed into a Bio-Rad running tank containing 1X running buffer (Appendix). Thirty 
microliters (30ul) of each sample were loaded into the wells. Also included as in one 
of the wells was 5 μL of the PageRuler™ Prestained Protein Ladder (Thermo 
Scientific, Europe). The set-up apparatus was connected to the Bio-Rad Power pack 
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200 and the gel was electrophoresed at 100 V/cm for 75 minutes. Following resolution, 
the protein was transferred onto a nitrocellulose membrane using the set up illustrated 
in Figure 4.1 below which was placed in the transfer unit of the Bio-Rad Mini 
PROTEAN© and the protein transfer took place for 90min at 100V.  
 
Figure 4.1: Illustration of set up used to in transfer of protein onto a nitrocellulose membrane 
 
Following transfer, the membrane was carefully removed from the “sandwich” and was 
washed briefly with PBS-Tween (Appendix). Ponceau S stain (source) (Appendix) was 
used to verify that the transfer was successful. 
For detection of GRXCR2 protein, the membrane was blocked in blocking buffer 
(Appendix) for 1 hour at room temperature with gentle agitation. This was followed by 
O/N incubation at 4°C with gentle agitation in blocking buffer containing a 1:1000 
dilution of the mouse monoclonal antiFLAG M2 primary antibody (Sigma Aldrich). 
Following O/N incubation, the membrane was washed twice for 10 min and twice for 
5 min with cold PBS Tween. Thereafter, the membrane was incubated in blocking 
buffer containing a 1:5000 dilution of the secondary polyclonal anti-Mouse goat 
antibody (Sigma Aldrich) for 1 hour at room temperature with gentle agitation. The 
membrane was then washed as described before and the protein detected by 
incubating in the dark in the Bio-Rad Clarity Western ECL Substrate (Thermo 
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Scientific, Europe) followed by exposure to x-ray film and developing and fixing of the 
exposed x-ray.  
 
Expression of GFP-tagged GRXCR2 protein in HEK293 cells and visualization using confocal 
microscopy. 
Cells were counted and 3.5x104 cells were plated per well in 35mm plates with 4 
chambers and a glass bottom, in order to achieve 50 – 60% confluence the next day 
which was the day they were transfected. The chamber allows for live cell viewing and 
imaging using the confocal microscope. 2ug of pEGFP-C1-GRXCR2WT, pEGFP-C1-
GRXCR2MT and pEGFP-C1 were incubated, respectively, with 4ul of X-
tremeGENE™ HP DNA Transfection Reagent (Roche) in 100ul of complete DMEM 
(10% FBS+1%Pen Strep) for 20 minutes at room temperature. Media was removed 
from cells and fresh 2ml complete media was added followed by the addition of 
plasmid-transfection reagent complex in a dropwise manner. After 48 hours incubation 
at 37°C with 5% CO2, live cells were viewed using a Zeiss LSM8800 with Airyscan 
confocal microscope (Zeiss, Germany). The detector of the confocal was the photo 
multiplier tube (PMT) and allowed detection of the green fluorescence signal through 
the Argon laser at 488nm. Images were visualised and processed using the ZEN Black 
Software (latest version) provided by Zeis. 
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Results 
Patients’ demographics 
Information regarding the age, gender as well as the age of onset of hearing loss for 
the South African and Cameroonian patient participants are summarised in Table 4.1. 
Sixty percent (60%) of the patients were males (n=48) with 70% of patients reported 
to have a prelingual onset of hearing loss. When investigating the transmission of 
hearing loss, 46,25% (n=37) were reported to have a family history of hearing loss, 
with most of this group being from Cameroon. The average age of the participants at 
recruitment was 12 years old and 14 years old for the Cameroonian and South African 
patients respectively.  
 
Table 4.1: Summary of Socio-Demographic data of patients 
 South African  
(n= 23) 
Cameroon  
(n=57) 
Total 
(n=80) 
Sex Male 16 32 48 
Female 7 25 32 
Age of Onset Prelingual 3 53 56 
Perilingual 6 0 6 
Postlingual 3 3 6 
N/A 11 1 12 
Transmission Familial 5 32 37 
Sporadic 13 22 35 
N/A 5 3 8 
Prelingual – Before the development of speech; Perilingual - Onset before speech development is completed; 
Postlingual – Onset occurred after the development of speech; N/A – No data is available in records. 
 
Thorough examination of Cameroonian patients at recruitment identified the cases to 
be sensorineural where the inner ear component is affected whereas the South African 
patients did not have this data available. Furthermore, the degree of hearing loss of 
the Cameroonian patients was determined using a sloping audiometric graph and is 
summarised in Table 4.2. Twenty nine (29) Cameroonian patients exhibited 
symmetrical loss of hearing, with 23 patients determined to have asymmetrical 
exhibition. No data was available 5 Cameroonian patients as well as the South African 
patients.  
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Table 4.2: Degree of Hearing loss of Patients 
Degree of hearing loss (dB) Cases % 
Severe 1 (71 – 80) 1 1.25 
Severe 2 (81 – 90) 1 1.25 
Profound 1 (91 – 100) 12 15 
Profound 2 (101 – 110) 9 11.25 
Profound 3 (111 – 120) 5 6.25 
Total HL (>120) 1 1.25 
Asymmetric 23 28.75 
Not determined 28 35 
Total 80 100 
Degree of hearing loss categories as provided by WHO. Patients are classified according the degree of hearing 
loss observed in the better hearing ear in cases of non-symmetrical hearing loss.  
 
Description of families selected for WES  
The multiplex families selected for WES are illustrated as pedigrees in Figure 4.2. The 
probands are all born to unaffected parents, strengthening the hypothesis that the 
mode of inheritance for the families is autosomal recessive.  
Family 4 (Figure 4.2A) has 3 affected siblings (out of 6) reported with prelingual onset 
of HL. The siblings were at varying ages at the time of recruitment with the youngest 
affected sibling being a 9 years old male (4.2A - II:1) presenting with non-symmetrical 
HL with the highest degree observed in the left ear at P2 and the right ear at P1. The 
other siblings are both female, aged 18 (A II:4) and 21 (A II:6) at the time of 
recruitment, presenting with symmetrical HL with a severity of P2 and P1 respectively. 
Following TGE, the family was resolved and showed that the affected siblings all 
carried an intronic variant in OTOF. The c.766-2A>G variant has been reported before 
as the causative variant resulting in ARNSHL (Yasunaga et al., 2000). 
Family 6 (Figure 4.2B) has unaffected parents with all three of their children reported 
to have congenital HL. During recruitment, only two of the three siblings were available 
for collection of blood samples for DNA extraction (B II:2 and II:3). Demographic data 
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was only collected for B II:2 which was a 3-year-old male, but the severity of HL was 
not recorded. Nonetheless, the availability of DNA from two of the three siblings 
allowed for the resolution of the family through TGE. The previously reported result 
showed that two novel variants, c.1678G>A and c.2007C>A, were identified in both 
probands in compound heterozygosity in the SLC26A4 gene. Also reported as a 
contributor to the HL was a complex copy number variation of the STRC gene.  
Family 8 had two affected children, a 6-year-old male and 9-year-old female, born to 
unaffected parents. Degree of hearing loss was measured at P2 for the female and 
appeared to be symmetrical however no audiological data was available for the male 
proband. Through TGE, no causative variant was picked up and the family remained 
unresolved. Secondary variants were reported in other genes but were not significant 
enough to be causative.  
 
A
 
B
 
C 
 
D 
Family 9 
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Figure 4.2: Pedigrees of multiplex families selected for WES following TGE. All families show at least two affected children 
born to unaffected parents. This strengthens the genetic nature of HL as well as the mode of inheritance as recessive. This 
was important to minimise or rule out unknown or unaccounted for environmental factors which plague the region. 
 
The fourth family, Family 9, has two affected brothers, aged 15 and 17, born to 
unaffected parents. Their audiological data shows a symmetrical degree of hearing 
loss of P1 in the 15-year-old and a non-symmetrical presentation of hearing loss with 
a degree of P1 in the right ear and P2 in the left year. This family, too, remained 
unresolved after TGE analysis through OtoSCOPE®.  
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Table 4.3: Summary of findings of each family from TGE through OtoSCOPE® and WES 
Family 
Otoscope findings Whole exome sequencing findings 
Gene Nucleotide change Protein change  Gene Nucleotide change  Protein Change 
4 
Causative Variants  OTOF c.766-2A>G intronic OTOF c.766-2A>G intronic 
Secondary findings 
CDH23 c.3361A>T  p.Ile1121Phe 
      
DFNA5 c.658G>A  p.Gly220Ser 
TMPRSS3 c.715T>C  p.Try239His 
USH2A c.14804G>A  p.Arg4935Gln 
USH2A c.12883A>G p.Ile4295Val 
USH2A c.4796G>A  p.Gly1599Asp 
6 
Causative Variants  
SLC26A4 
c.1678G>A  p.Asp560Asn 
SLC26A4 
c.1678G>A  p.Asp560Asn 
c.2007C>A  p.Asp669Glu c.2007C>A  p.Asp669Glu 
STRC Complex Copy Number Variation -    
Secondary findings 
CDH23 c.3038A>C  p.Asp1013Ala PAX3 c.1320C>T p.Asp440Asn 
GJB3 c.300B>C  p.Glu100Asp MYO7A c.4878_4879insT p.Ser1628frameshift 
MYO7A c.6002C>T p.Thr2001Met MYO7A c.6002C>T p.Thr2001Met 
TRIOBP c.3068C>T  p.Ala1023Val     
WFS1 c.854G>A  p.Arg285His     
8 
Causative Variants  -     GRXCR2 c.251delC p.Arg84Frameshift 
Secondary findings 
CDH23 c.6329C>T  p.Ala2110Val  -     
CDH23 c.6596T>A  p.Ile2199Asn     
GPR98 c.463A>G  p.Ile155Val     
MYO7A c.5065G>A  p.Asp1689Asn     
TPRN c.1259C>T  p.Pro420Leu     
TRIOBP c.202A>G  p.Thr68Ala     
USH2A c.13409C>T  p.Pro4470Leu     
9 
Causative Variants  -   -     
Secondary findings 
GPR98 c.6383G>A  p.Arg2128Gln -     
LRTOMT c.*1867T>A intronic     
MYH14 c.262C>T  p.Arg88Trp     
MYO15A c.3359G>A p.Arg1120His     
MYO7A c.*546C>T intronic     
USH1C c.1069C>T  p.Arg35Tro     
USH2A c.8575C>T  p.Arg2859Cys     
WFS1 c.482G>A  p.Arg161Gln       
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Panel sequencing findings are replicated on WES 
In Family 4, 2 of the 3 affected siblings were subjected to WES and confirmed to carry 
the c.766-2A>G in the OTOF gene identified previously through OtoSCOPE® (Table 
4.3). This intronic variant results in a splicing error that skips exon 9 and introduces a 
premature stop codon in exon 10 resulting in a truncated protein. This variant is 
automatically disease causing as called by mutation taster, which is the highest 
category given by the programme.  
Similarly, in Family 6, WES reported 5 novel variants as possible candidate causative 
variants, 2 of which were the same variants reported through TGE (Table 4.3) as 
causative variants in the SLC26A4 gene. The other novel variants identified through 
WES were in PAX3 and MYO7A but were excluded on account of their possible 
syndromic manifestation as well as their suspected dominant pattern of inheritance, 
both of which did not fit the ARNSHL phenotype observed in the family. 
The causative variant for Family 8 was identified through WES as the homozygous 
deletion of a cytosine at position 5:145252279 in the GRCh37 human reference 
genome build. 
No causative variants were identified for Family 9 through WES. A summary of the 
findings in these families is presented in Table 4.3. 
 
Confirmation of a novel HI gene (GRXCR2) with a novel causative variant  
The novel variant identified at position 5:145252279 corresponds to a homozygous 
deletion within a gene called Glutaredoxin and Cysteine Rich Domain Containing 2 
(GRXCR2). It is located on chromosome 5 (5q32) and spans about 14.49Kb and is 
transcribed from the reverse strand. It has 3 exons, all of which are coding, and 
translates into a 248-residue long protein of a size of about 28kDa. The novel 
c.del251C variant was categorised as pathogenic by Mutation taster the highest 
pathogenicity category by the programme.  The novel c.251del_C variant is in exon 1 
and was confirmed by Sanger sequencing (Figure 4.3.).  
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Figure 4.3.: Partial chromatograms of exon one: Sanger sequencing results validating the presence of the c.251del_C variant 
in patients (A) and the retention of the cytosine in a control sample (B). There is a homozygous deletion as identified in whole 
exome sequencing.  
 
Upon validation of the presence of the variant in our probands, we observed 
evolutionary conservation of this base across 8 primate species when aligned against 
one another (Figure 4.4.).  
 
 
Figure 4.4: Evolutionary conservation of portion of GRXCR2 in higher primate species with affected codon showing 
conservation: The sequence of the codon and surrounding codons have been maintained across these higher primates which 
can infer the biological and functional importance of the base. 
 
 
GRXCR2 protein 
The GRXCR2 gene is expressed in the inner ear during development and trace 
amount of RNA has been detected in the foetal heart tissues and in adult testes 
(Schraders et al., 2010). The GRXCR2 protein belongs to the glutaredoxin domain 
containing family. This is due to the presence of region with sequence similarities to 
glutaredoxin proteins. It is also a paralog to GRXCR1 to which it has a protein 
sequence similarity of 33.06%. Other features of the protein are the cysteine-rich 
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domain at the C-terminus end which has a predicted zinc-finger motif. Experiments 
conducted have shown that the N-terminus domain is responsible for localization of 
the protein which seems to be prominent on the cell membrane, particularly on cellular 
projections such as stereocilia bundles of the inner and outer hair cells of the inner ear 
(Avenarius, 2012). The identified variant contains a deletion of a cytosine base which 
corresponds to position 251 in the cDNA sequence. 
The pathogenicity of the variant was further explored by the predicted change it would 
have on the amino acid sequence due to the frameshift nature of the c.251del_C 
variant. Protein sequence prediction by ExPASy and EMBOSS Trans revealed the 
altering of the amino acid sequences after p.R84 as well as the introduction of a 
premature stop codon at position 116 of the amino acid sequence (Figure 4.5.). 
 
 
MEDPEKKLNQKSDGKPRKVRFKISSSYSGRVLKQVFEDGQELESPKEEYPHSFLQESLET 
MDGVYGSGEVPRPQMCSPKLTAQRSVCLERVMPTPWQAASLGSTITRRMTISPYLL*  
Figure 4.5: Protein translation sequence of GRXCR2 in the presence of the c.251del_C variant. Yellow highlighted residues 
indicate residues which are altered in exon 1. Grey highlighted bases are altered in exon 2 and the * denotes the premature 
stop codon. 
 
In order to begin understanding how the alteration of the protein sequence and size 
affect functionality, we first sought to investigate, in silico, the secondary structure of 
the wildtype GRXCR2 protein. PSIPRED returned a profile which depicts the predicted 
secondary structures and their position along the protein sequence. GRXCR2 is a 
relatively small protein with its secondary structure depicted mostly random coiling and 
few helices and beta sheets (Figure 4.6.). Comparison of the wildtype and the mutated 
sequence was not possible as the 115 residues long sequence is too short to be 
interrogated in PSIPRED. 
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Figure 4.6.: Secondary structures of GRXCR2 by PSIPRED. Orange vertical line denotes the site of the base deletion and 
alteration of protein sequence. The red vertical line denotes the position of the premature stop codon. 
 
The predicted stability of the protein post translation can also give insight into the 
behaviour of the protein in the cell. Shown in Figure 4.7 is the disorder profile of the 
protein according to identified Intrinsic Disorder Regions (IDRs) which are regions in 
the protein that can alter their state from structured to unstructured as a protein 
prepares to or carries out it functions, particularly in binding with other proteins. 
GRXCR2 was found to have three distinct protein binding regions corresponding with 
high confidence of IDRs. Truncation of the protein leads to the loss of the C-terminus 
IDR which includes the cysteine rich region which is predicted to fold into a zinc-finger 
structure known to act in protein-protein interactions. 
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Figure 4.7: DISOPRED3 Intrinsic Disorder profile of GRXCR2 with protein binding regions. Red vertical line denotes truncation 
of protein. 
 
Given the presence of protein binding sequences or regions within GRXCR2, potential 
predicted protein-protein interactions (PPI) were investigated using STRING 
database, but no data was available for GRXCR2. 
 
Exploration of GRXCR2 for additional variants in HL cohort through Sanger Sequencing 
We investigated the frequency of this variant in our patient and control cohort of both 
South Africans and Cameroonians. The variant was identified in one other proband 
(patient 34), unrelated to the members of Family 8 (Figure 4.8.). 
 
80 
A. Pedigree 
 
B. Electropherogram 
 
Figure 4.8.: Pedigree of simplex family (A) and Electropherogram showing presence of c.251del_C in the probands (B). 
 
This isolated unrelated patient is a female who was 8 at the time of recruitment. She 
exhibited non-symmetrical hearing loss with a severity of P1 in the left ear and S2 in 
the right ear. 
Identification of the identified novel variant in a second unrelated case prompted the 
sequencing of the other 2 exons to identify any other variants harboured within 
GRXCR2 by this cohort. No other novel variants were observed in the rest of GRXCR2. 
Two polymorphisms were identified, both of which do not seem to be disease causing 
(Table 4.4). Despite c.543A>C being a missense variant, it carries a high minor allele 
frequency and is tolerated in the gene product and is thus not disease causing. 
 
Table 4.4.: Variants identified in exon 2 and exon 3 of GRXCR2 from sequencing of the entire 
patient cohort. 
Genomic 
position 
Nucleotide 
change 
Protein 
change 
Pathogenicity 
(According to 
Mutation taster, 
Mutations tester 
and SWIFT) 
Cameroonian South African 
Alleles 
(homozygous) 
Alleles (homozygous) 
5:145866522 c.543A>C p.Leu181Phe Tolerated 10/114 (2) 5/23 (0) 
5:145866555 c.510C>T p.His170= Benign 4/114 (0) 0/23 
 
 
Functional Studies 
Confirmation of premature stop codon through western blotting 
To be able to visualise the effect of the variant on the translation of the ORF, western 
blotting was used. The detection of the DDK-tag downstream of the GFXCR2 ORF in 
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the pCMV vector allowed for visual confirmation of a premature stop codon in the 
GRXCR2MT ORF. In the case of the WT protein, the tag will be expressed and 
therefore detected, while in the case of the variant, the protein will be prematurely 
truncated and hence not express a DDK-tagged protein. HEK293 cells were 
transfected with plasmids expressing either the WT or the mutant protein. Total protein 
was isolated, separated using SDS-PAGE, and then transferred onto nitrocellulose 
membrane. To confirm the successful transfer of protein from the SDS-PAGE gel to 
the nitrocellulose membrane, a Ponceau S stain was performed (Figure 4.9), which 
shows successful transfer of equal amounts of protein for the two lanes which carry 
the pCMV-GRXCR2WT and pCMV-GRXCR2MT protein lysates. 
 
 
Figure 4.9: PonceauS staining showing successful transfer of protein from gel to nitrocellulose. Lane PL is the pre-stained 
protein ladder PageRuler (Thermo Scientific, Europe). Lane LMP-1 is a positive control for the DDK\FLAG tag antibody. Lane 
GRXCR2WT is loaded with total protein lysate from cells transfected with wildtype ORF. Lane GRXCR2Mt is the protein lysate 
from cells transfected with the mutated GRXCR2 ORF.  
 
Following western blotting using an anti-body specific to the DDK/Flag tag, a clear 
dominant band of the predicted size was observed for the WT protein, which was 
absent for the mutant protein (Figure 4.10.).  
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Figure 4.10.: The c.del251C GRXCR2 mutation prevents detection of DDK/FLAG: HEK293 cells were transfected with the 
pCMV-GRXCR2WT or GRXCR2MT expression constructs. Western analysis of whole cell protein lysates from the transfected 
cells indicated GRXCR2WT steady state levels were significantly higher than GRXCR2MT levels.  
 
This demonstrated the detection of the DDK/FLAG tag downstream of the GRXCR2 
in the wild type and the inability to detect it in the mutant at the corresponding band 
size, confirming a disruption in the translation of the DDK/FLG due to the predicted 
premature stop codon. 
 
Live imaging HEK293 cells transfected with WT or MT GFP-GRXCR2 proteins using confocal microscopy 
Visualisation of the protein in the cell was made possible by fusion of the WT and 
mutant protein to GFP through sub-cloning into the pEGFP-C1 vector, which inserts 
the GFP tag in frame into the ORF on the N-terminal end of the protein. Following 
transfection into HEK293 cells of vectors expressing GFP-GRXCR2WT or GFP-
GRXCR2MT or empty vector (GFP expressing only), visualization was done using the 
confocal microscope at 48 hours post-transfection. As is shown in Figure 4.11, cells 
transfected with the empty vector showed strong and uniform pattern of expression 
throughout the cells. Transfection of HEK293 cells with the empty pEGFP-C1 also 
served as verification of the GFP expression and detection. 
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Figure 4.11.: Representative cells showing expression of GFP in HEK293 cells: (A-C) HEK293 Cells showing different 
intensities of uniform GFP expression when transfected with the GFP-Empty vector.  
 
For WT-GTP tagged GRXCR2, the protein seemed to be preferentially localized 
outside of the nucleus and predominantly in the cytoplasm, with some punctate 
staining close to the periphery of the cell membranes (Figure 4.12 – top panels). This 
suggests that the WT protein is expressed in the cytoplasm, where it is confined, and 
potentially shuttled to the periphery close to the membrane. Since these cells were 
visualised live, a DNA specific stain could not be used to locate the nuclei. Staining of 
the DNA required fixation of the cells which led to leakage of GFP outside of the cells 
and therefore could not be performed. Interestingly, and in contrast to the GFP-
GRXCR2WT protein, the mutant GRXCR2 protein lacked any particular localization 
within the cells and showed a distribution similar to that observed for the empty vector, 
although at a seemingly lower intensity (Figure 4.12 lower panel).  
 
A B C
 
 
A 
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Figure 4.12:Represntive cells showing expression of GFP-GRXRC2WT(Top) and GFP-GRXCR2MT(bottom) in HEK293 cells: (A-
B) Both panels show distinct darker regions owing to shuffling of recombinant protein out of the nucleus.(C-E) GFP with 
mutant GRXCR2 shows uniform expression with decreased intensity. No darker regions seen in top panel were not observed 
in this construct. 
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Discussion 
Originality and Strengths 
Next generation sequencing has increased the rate of discovery of variants associated 
with various diseases, including HL (Atik et al., 2015). However, accessibility to 
infrastructure and funds for such ventures are not always available in developing 
countries, specifically those in SSA. To date, few papers have been released with data 
on NGS used to resolve cases of HL in this population group, and more specifically, 
the use of TGE (Shearer et al., 2014b; Bademci et al., 2016; Lebeko et al., 2016; 
Rudman et al., 2017). Results of these studies show that there is still a lot to be 
uncovered about the genetic spectrum of HL in sub-Saharan African populations. Our 
study is the first to use WES to resolve cases of ARNSHL in multiplex families from 
SSA (Cameroon). It has demonstrated the efficacy of this approach in being specific 
enough to identity variants in known genes but equally sensitive enough to identify 
variants in unknown genes, or genes not yet associated with HL. This is seen by the 
low number of newer genes being discovered as contributors to the disease even 
when using WES in Caucasian, Asian and Middle Eastern Populations (Atik et al., 
2015). Only 22 new genes have been uncovered through WES compared to the 
already 180+ known genes. If there is an increase in the number of WES analysis 
performed on Sub-Saharan African groups, it is likely that this will lead to an increase 
in the discovery of new genes associated with HL.  
 
Targeted Gene vs Whole Exome sequencing 
In our study cohort of 10 families, we were able to resolve 7 of the families using the 
then latest version of the OtoSCOPE® (Lebeko et al. 2016). This high-resolution rate 
of 77% can be attributed to the clinical selection of only families with multiple members 
and therefore highly likely to be display a HI of genetic origin, that could not be the 
case with simplex cases, as reported in previous studies with lower pick-up rate among 
Africans (Sloan-Heggen et al., 2016; Shearer et al., 2014b; Rudman et al., 2017; (Yan 
et al., 2016). Indeed, the overall trend seen among patients of African descent is that 
of having the lowest resolution rates when screening for variants in known HL genes 
and comparing the results to other populations group using the same panel (Sloan-
Heggen et al., 2016; Shearer et al., 2014b; Rudman et al., 2017) and other TGE HL 
panels (Yan et al., 2016). We reported five novel variants in 7 families, while the 
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number of new variants identified within different European and Asian populations 
groups is not showing an increase (Shearer et al., 2014b; Rudman et al., 2017). The 
variants identified in our multiplex families through TGE were not present in the rest of 
our singleplex cases. This could be due to multiple reasons: 1) the limited number of 
families studied  that may not have captured the most common genes in the studied 
population, 2) the extreme genetic diversity of HL that will required hundreds of 
families studies a  have an appropriate population profile in a given country, 3) the 
great genetic diversity of the population in Cameroon that will favour private or regional 
mutations prevalence (Lambert and Tishkoff, 2009). In addition, while data suggest 
that the discovery of new HL genes and variants is reaching saturation in the more 
widely screened populations (Caucasian and East Asian), our study suggests the 
possibility of discovering novel genes through 2/9 Cameroonian families investigated. 
The data advocates for the inclusion of a more diverse population group i.e. Africans, 
and also the relevance of using a wider approach such as WES. Indeed, the selection 
of 4/9 families for WES, two of which we had identified causative variants through 
targeted panel support the use of WES rather than targeted panel in under studied 
population such as sub-Saharan Africans. Through WES in this sub-set, we saw a 
75% resolution rate among the families which is higher than the 50% seen through 
OtoSCOPE® for the same four families. The identification of the same variants in two 
previously resolved families and the resolution of a previously unresolved family has 
demonstrated that, with appropriate coverage, WES is sensitive enough to detect 
these variants in known genes while simultaneously being comprehensive enough to 
identify causative variants in novel genes. The efficacy of this approach was also 
demonstrated in a multi-ethnic cohort from different regions around the world which 
saw a 56% resolution rate using WES (Bademci et al., 2016). Additionally the authors  
confirmed that copy number variations’ contribution to HL can also be explored 
through WES when building the filtering pipeline (Bademci et al., 2014; Shearer et al., 
2014a). There remains an unresolved multiplex family in our cohort which could point 
to the need of a more comprehensive filtering pipeline. This be could due to a complex 
structural change which was not detected by WES or a variant in other parts of the 
genome which was not captured by WES and would be discovered through Whole 
genome sequencing (WGS), though this presents with challenges of its own. The 
closest approach used to WGS was whole genome SNP mapping which was able to 
resolve 100% of 30 families from Pakistan (Shafique et al., 2014). This panel captures 
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and genotypes more than 700 000 SNPs across the human genome which can be 
filtered similarly to a WES approach. When working with patients or populations of 
African descent, this might not be as effective due to the data that informed the 
development of such panels usually has a very low representation of data from 
individuals of African ancestry.  
However, in order to build a comprehensive genetic profile for African patients with 
HL, the present data indicate that WES is the best next approach and should be the 
go-to step for clinical and research settings to allow for the identification of new 
variants as well as new genes which are contributing to the loss of hearing.  
 
Identification of variants in GRXCR2. 
Whole exome sequencing identified a novel variant in GRXCR2 in the probands of 
“Family 8” which was previously unresolved through TGE. The c.251delC was 
identified in homozygous state in the affected members and confirmed by Sanger 
sequencing. In silico investigation of this variant showed that this frameshift variant 
results in the introduction of a premature stop codon and ultimately the truncation of 
the protein, and is predicted disease causing by several tools including mutation taster. 
Furthermore, we identified this variant in a singleplex HL case following screening of 
our cohort and matched controls. The presence of the variant in another unrelated 
patient strengthens the hypothesised contribution of this variant to HL. When looking 
at the background of our probands and the singleplex case, we found that they come 
from distinct regions of Cameroon of different ethnolinguistic group. The multiplex 
family is from a Northern region of Cameroon known as Ngaoundere and are from the 
Fulani ethno-linguistic group. The second patient found to be carrying this variant is 
from Bafoussam in the western Cameroon, on and is of the Bamiléké group. However, 
this variant could be a founder variant and compels one to theorise that the variant is 
not restricted to one group or region and could be found elsewhere within the greater 
West African region if not other parts of the continent. Indeed, the NHIBI Exome 
Sequencing Project reports a single heterozygous carrier of this variant whom is 
reported as an African American individual (http://evs.gs.washington.edu/EVS/) 
further highlighting the potential presence of this variant within the African population 
from the diaspora. One can thus recommend that this gene be further explore in 
multiple African populations with ARNSHI. Notably, the GRXCR2 c.714dupT mutation 
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was identified in a Pakistani family with HL (Imtiaz et al., 2014); therefore the present 
report in an African  family and a patients confirm the implication of GRXCR2 in 
ARNSHI in humans. 
 
Focus on GRXCR2 
The glutaredoxin and cysteine rich domain containing 2 (GRXCR2) gene is found on 
chromosome 5 and has three exons which encode a cysteine rich protein that is 248 
residues long. It is a paralog of GRXCR1 and both have been shown to be required 
for stereocilia bundle development, organization and maintenance (Avenarius, 2012). 
GRXCR2 is expressed in the sensory hair cells of the inner ear, with trace amounts 
detected in the heart and testes. Pirouette mouse models showed variants in GRXCR1 
to result in hearing loss with vestibular dysfunction (Odeh et al., 2010). A similar 
syndromic phenotype was observed in humans who carried pathogenic variants in this 
gene (Schraders et al., 2010). Importantly, null mutations in GRXCR2 in mice results 
in early onset progressive hearing loss without vestibular dysfunction (Avenarius, 
2012), a phenotype observed in our present study as well in previously reported family 
(Imtiaz et al., 2014). The differences observed in the phenotype between variants in 
GRXCR1 and GRXCR2 suggests the proteins might have slightly distinct roles in the 
stereocilia maturation pathway. This is further seen by differences in the organisation 
and structure of stereocilia in the presence of variant in GRXCR2 or GRXCR1 
(Avenarius, 2012). 
GRXCR2 has three functional domains, one of which has a sequence similarity to 
glutaredoxin. Members of this protein family are enzymes that use glutathione as an 
electron donor in the reduction of oxidized cysteines of other proteins (Holmgren, 
1989). However, conserved residues required for this action are absent in the 
GRXCR2 sequence thus, this protein is unlikely able to carry out this function 
(Holmgren, 2000). Other domains within GRXCR2 include a cysteine rich domain 
(Cx2Cx7Cx2Cx20Cx2Cx7C) at the C-terminus end with a zinc-finger motif. This 
conformation has been extensively shown to be needed in protein-protein interactions. 
The disruption of this domain, as result of the c.714dupT results in an extension of the 
C-terminus, creating an N-glycosylation motif that signals the protein for degradation, 
leading to the HI phenotype observed in the affected members of the Pakistani family 
(Imtiaz et al., 2014). The novel c.251delC variants we found introduces a premature 
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stop codon at position p.116 which results in a truncated protein without a (functional) 
C-terminus cysteine rich domain (Figure 4.7.). It is most likely that PPIs mediated by 
this domain are essential for the GRXCR2 functionality, particularly in the formation of 
homodimers or other protein complexes. This too was investigated by Avenarius and 
showed strong evidence for GRXCR2 homodimerization, as well as GRXC1 
homodimerization. However, experiments relating to their interaction with one another 
were not conclusive. Improvement on these experiments as suggested by Avenarius 
could give further insight to these two paralogues interactions. One could compare this 
hypothesis to the interaction seen in the Connexin family between GJB2 and GJB6 in 
their heterodimerization needed for functionality while still showing evidence of distinct 
roles seen by their different disease manifestations (Xu and Nicholson, 2013) 
Nonetheless, the evidence is enough to provide the mechanism by which these two 
GRXCR2 variants affect this protein with regards to the Cysteine rich domain and how 
this could contribute to the destabilization of stereocilia in the absence of functional 
GRXCR2 multimers.  
Gene ontology for GRXCR2 described the molecular function as being a heat shock 
protein as well as being involved in unfolded protein binding. When looking at the 
intrinsic disorder profile, we identified three regions showing IDR properties with 
inferred protein binding. The IDRs are most likely essential sites in the protein that 
carry out the chaperone function. That is to help new proteins stabilize and fold 
correctly as well as to refold proteins that were damaged by cellular stress. Given the 
disease onset and progression of HL, it is possible that GRXCR2 is responsible for the 
development, maturation and maintenance of stereocilia bundles in this mechanism. 
In its absence, inner and outer hair cells of the inner ear have an incorrect arrangement 
due to errors during the developmental phase, owing to the absence of a chaperone 
to help stabilize and ensure correct folding of components of the bundle. Additionally, 
the mechanism of action on the hair cells is a stress that affects the stability of 
stereocilia bundles and without the refolding of proteins, this structure deteriorates 
over time and is seen by the progressive nature of HL seen in patients with causative 
variants in GRXCR2. And if indeed tetramers of GRXCR2 are needed for functionality, 
abolishment of the cysteine rich domain would result in a null effect causing the above 
described scenarios. Establishment of the definitive PPI of GRXCR2 will give great 
insight to its role in the stereocilia bundle maturation as well as its position within the 
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network of HL genes. Potentially, gene therapy could be explored for this type of HL 
as the stereocilia could be maintained and repaired even if they were poorly organised 
and hearing could be maintained for much longer periods. 
 
Functional studies were used to elucidate the mechanism of the pathogenic effect of 
the c.251delC variant in vivo. We selected the HEK293 cell line to express the protein 
and used it as a model for the inner ear hair cells due to its apical surface which can 
be a model for the stereocilia. This means the cellular architecture is similar such that 
the mechanism by which proteins are localised to the apical surface are similar to 
those used for proteins localised to the stereocilia of the inner ear hair cells.  
Expression of a c-terminal tag was not detected in western blot analysis of the mutated 
GRXCR2 protein confirming the presence of a premature stop and aligned with result 
from the in silico prediction of the translation of the mutated sequence. The effect of 
the variant on cellular localisation was explored through creating fusions with GFP of 
both the WT and the mutant protein on the N-terminal side. The role of the N-terminus 
domain in localisation of the GRXCR2 protein was well demonstrated by Avenarius in 
his PhD thesis (Avenarius, 2012). This showed proteins lacking either the C-terminus 
domain or the central glutaredoxin-like domain were still able to localise to the apical 
surface and showed protein lacking the N-terminus domain failing to localise to the 
apical surface and were detected in the cytoplasm and nucleus (Avenarius, 2012). The 
wildtype GRXCR2 protein seems to allow for transportation towards the periphery and 
is more concentrated towards the cellular membrane where we find the apical 
structures with similar architecture as the stereocilia of inner ear hair cells. This could 
be due to the PPIs between GRXCR2 proteins which allow for its localisation to the 
cellular membrane. Thus, we see the GRXCR2 protein able to carry out its function 
even with the GFP protein fused to it. In the mutated GRXCR2 protein, we observed 
a decreased intensity in the GFP fluorescence when compared to the empty pEGFP-
C1 vector and also did not observe a migration towards the periphery of the cell as 
seen in the wildtype GRXCR1 protein construct. This could be due to that the pEGFP-
C1 plasmid is small and more of it is transported into cell as compared to the plasmid 
with the ORF. Another factor could be the degradation of the complex due to the 
truncated GRXCR2 or an expression inefficiency also due to the presence of the 
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truncated GRXCR2 protein. The presence of the GFP upstream of the GRXCR2 
protein is not enough to justify the lack of migration in the mutated GRXCR2 as this 
function was still carried out in the wildtype. In order to elucidate the effect of the 
variant on the protein in the absence of GFP upstream, GRXCR2 specific antibodies 
can be used in an immunohistochemistry experiment as well as adding 
markers/staining for various organelles to paint a full picture as to the expression and 
migration pattern of the truncated GRXCR2. Nonetheless, the evidence presented 
supports the argument of this variant alters the functionality of the protein such that it 
is not able to carry out normal functions as in the wildtype which lead to the support of 
stereocilia bundles during growth and maturation as well as their maintenance during 
functioning. 
 
Limitations 
Though we have shown the efficacy of WES in resolving cases of ARNSHL in African 
patients and have shown sufficient evidence to the pathogenicity of the c.251delC 
variant in GRXCR2 as well as postulated to the mechanism of action of the protein 
and its contribution to hearing and thus HL in its absence, there is room for 
improvement in this presented study. The presence of the variant in a second case 
points towards the possibility of a founder effect with regards to this variant. We were 
not able to explore this further due to lack of DNA material from the probands and the 
affected patient. In our functional studies, the use of GRXCR2 specific antibodies 
could have increased accuracy of both localisation and protein expression levels. 
Further exploration of this could have given a bit more clarity in terms of the exact 
mechanism that is disrupted by the truncated protein. DNA specific stains to visualise 
the nucleus could not be used in this experimental design as fixing of HEK293 cells 
onto glass slides resulted in leakage of GFP which prevented detection.  
 
Conclusions 
We have demonstrated the efficacy and accuracy of using WES in clinical setting to 
resolve HL in a multiplex family from Cameroon, by identifying a novel c.251delC 
variant harboured in GRXCR2, in two unrelated patients, and confirming the 
implication of this genes in HL in Human, as it was only reported one in a different 
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population. Additionally, we have shown that WES is able to detect variants in known 
HL genes, by replicating the results uncovered through TGE on the OtoSCOPE® 
panel. This further strengthens the advocacy of using WES in further exploring genetic 
causes of HL in African patients instead of using available TGE panels. In silico tools 
as well as functional studies demonstrated the pathogenicity of our novel c.251delC 
variant harboured in GRXCR2, as well as provided some insight to the possible role 
of the protein in the stereocilia maturation pathway. Identification of the variant in a 
second patient strengthens the association of the variant and HL as well as points 
towards a possible founder effect which needs to be further investigated.  
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Chapter 5: Overall Discussion, Conclusions and Perspectives 
 
Burden of Hearing Loss 
Hearing loss is sometimes called the silent disease as it is not visibly obvious who 
suffers from it or is affected by it and often times, ironically are not heard. This is well 
articulated by Olusanya and Newton as they demonstrate the oversight of the burden 
of disease of congenital HL in comparison to other ailments in the DALYs report 
(Olusanya and Newton, 2007). In the developing world, the burden of HL is felt more 
heavily due to its concurrence with unfavourable economic circumstances (Olusanya 
and Newton, 2007). This, coupled with stigma and isolation of both the patient and 
their family, contributes to a decreased quality of life. Patients have decreased access 
to education and ultimately employment and end up being a burden to the state for 
much of the duration of their life (Ruben, 2000; Schroeder, 2006). Early detection 
through rapid diagnostics is one way to try and mitigate these negative consequences. 
It allows for families and communities to be better prepared for the presense of hearing 
impaired individuals. In developed countries, screening programmes for newborns 
greatly assist in the management of HL and sees a lesser lifelong burden (Morton and 
Nance, 2006). This has partially been made possible by knowledge on the genetic 
causes of HL specific to their respective population groups (Atik et al., 2015). The 
extensive investigation of causative genes and their variants has allowed for the 
development of various HL panels such as OtoSCOPE® (Shearer et al., 2010), 
MiamiOtoGenes (Tekin et al., 2016) and OtoSeq (Shahzad et al., 2013). Outside of 
these vast panels, researchers have also been able to narrow down their screening to 
few a specific HL genes and variants known to be more prevalent in their respective 
population groups. The refinement of the number of genes and variants screened from 
those available on the above mentioned panels saves costs and analysis time. This 
makes the tools more easily accessible, thus increasing their feasibility in being used 
in a routine clinical setting. Such advancement is a result of continuous research 
spanning decades within predominantly Caucasian and Asian population groups 
which lead to the most common genes and variants being uncovered. In order to work 
towards the alleviation of the burden of HL, particularly in the most affected and 
vulnerable developing regions, there needs to be a continuous effort towards the 
discovery, building and refining of the genetic profile of HL genes across the greater 
sub-Saharan region, home predominantly to patients of African descent. Knowing that 
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this population group is vastly diverse (Lambert and Tishkoff, 2009), it is unlikely that 
one gene panel would suffice, but rather region specific panels would ultimately be the 
most useful. A strategy that could see improvement in diagnosis capacity, early 
intervention and ultimately of the improvement in basic healthcare services across the 
regions. However, we see that even in a relatively more developed country such as 
South Africa, the implementation of screening, be it at birth or during school going 
years is still far from where it needs to be (Petrocchi-Bartal and Khoza-Shangase, 
2016). This could mean there are potentially far more cases of HL that go by 
unreported and undetected until much later in the affected child’s life in South Africa 
(Gardiner et al., 2018). There is terefore an urgent needs to provide early screening 
and detection in SSA, including the incorporation of genetic screening that would also 
prepare families and potentialy alleviating anxiety and increase quality of life (Gardiner 
et al., 2018). 
 
Most prevalent hearing loss genes and variants are absent in sub-Saharan Africans 
The most prevalently reported and associated HL genes are connexin genes GJB2, 
and GJB6. These genes have been extensively screened across various populations 
and the causative variants identified have shown to be region and populations specific 
(Rodriguez-Paris and Schrijver, 2009; Chan and Chang, 2014). An example of such 
findings is with c.35delG of GJB2 and del(GJB6-D13S1830) of GJB6 that are able to 
resolve HL in up to 50% of HL cases among patients of European descent (Chan and 
Chang, 2014). Additionally, the founder variants c.235delC and c.167delT within GJB2 
have been identified among patients in East Asia and among patients of Ashkenazi 
Jews ancestry respectively (Dzhemileva et al., 2010). However, exploration of these 
genes in 100 patients from South Africa and Cameroon showed them to not be 
significant (Bosch et al., 2014a, 2014b). These findings were also demonstrated in 
other regions of SSA (Samanich et al., 2007; Shan et al., 2010; Trotta et al., 2011; 
Javidnia et al., 2014; Lasisi et al., 2014); the present thesis has contributed to support 
this (Lebeko et al, 2015). This is with the exception of a population group in Ghana 
which revealed a GJB2 founder variant have been found to be prevalent (Hamelmann 
et al., 2001). With such a rate of high genetic variation in Africans, and high genetic 
heterogeneity of HL, a wider comprehensive approach is more useful when trying to 
uncover genes that will be useful in clinical screening (Lebeko et al, 2015). 
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Next Generation Sequencing Technologies in Hearing loss 
The NGS approach has been used to explore different diseases, both Mendelian and 
complex. Given that the most prevalent mode of inheritance for HL is autosomal 
recessive, identifying variants contributing to HL through NGS technology is relatively 
easy as one expects to detect a homozygous or a compound trans heterozygous 
change in both copies of the gene that alters or abolishes protein functionality. Initially, 
the recruitment of consanguine families from North Africa through to the Middle East 
presenting with ARNSHL allowed for the elucidation of several genes which have 
subsequently been investigated in other populations around the world (Hilgert et al., 
2009). The high homozygosity between family members helped to narrow down 
regions where variants were co-segregated with HL. However, the occurrence of 
consanguine families is not common in many other parts of the world and thus 
homozygosity mapping and candidate gene screening is not always ideal (Ropers, 
2007). Within the African setting, making use of NGS to explore both known and 
unknown genes is the most ideal approach as there already exists a plethora of 
associated genes. This approach also ramifies the process and will help cover as 
many regions in a short space of time as it is very likely that there will be several 
candidate genes within smaller regions and even more within the entire sub-Saharan 
African population group (Atik et al., 2015; Rudman et al., 2017). As mentioned before 
NGS technologies have varying degrees of coverage. From whole genome 
sequencing, where the entire human genome of 3.5 billion bases are sequenced to 
WES where only about 1% of the genome is captured to TGE where a selected 
number of genes are investigated. Each of these approaches have their own pros and 
cons.  
Whole genome sequencing would allow for the interrogation of the entire human 
genome. This would most certainly resolve the genetic cause of HL in “family 9” which 
remains unresolved. As straight forward as this sounds, there are still a few challenges 
which need to be overcome before this approach can be implemented or even become 
the bread and butter of genetics research and personal medical care. Currently the 
cost of sequencing the entire human genome at a sufficient depth of coverage for 
accurate diagnosis is still quite high compared to WES. There is also no consensus 
on the format for the storage of this genetic data and the bioinformatics training 
required to analyse these large data sets is still lagging, especially on the African 
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continent. Currently no study has attempted to sequence the entire human genome in 
the investigation of genetics causes of HL. In the meantime, other NGS approaches 
such as WES and TGE are readily available as stepping stones to grow and perfect 
the exploration of the human genome in diagnostics and personal medical care in all 
diseases. 
 
Targeted Enrichment Panels in Hearing loss  
Realising that HL genetic spectrums are probably population and regions specific, 
several research groups have begun the quest of creating diagnostic panels for HL 
relevant to their population groups. The criteria behind which genes are included on 
these panels and which ones are left out are different for each panel. Nonetheless, all 
the panels are following the principle of targeted gene enrichment of known HL genes 
in order to elucidate the causative variant of patients presenting with HL. More 
resources are spent on getting high coverage of the selected genes thus increasing 
the accuracy of the reads and results. Analysis is also greatly simplified as the genes 
and their function are mostly known  
Several HL panels are currently used in clinical practice, such as OtoSCOPE® 
(Shearer et al., 2010, 2013; Moteki et al., 2016; Sloan-Heggen et al., 2016) , 
MiamiOtoGenes (Tekin et al., 2016; Yan et al., 2016), and OtoSeq (Shahzad et al., 
2013; Sivakumaran et al., 2013). These panels have a varying number of genes on 
the panels with the latest released panel (MiamiOtoGenes) having 180 genes (Yan et 
al., 2016). A larger custom panel included both mice and human genes which brought 
the gene number up to 246 genes (Brownstein et al., 2011). The resolution rates 
across these panels varies across the populations on which they are used, with the 
middle eastern populations consistently displaying the highest detection rates and the 
African populations, showing the lowest (Sloan-Heggen et al., 2016; Yan et al., 2016).  
The drawback of the panels could be seen when one looks at the selection criteria of 
the genes themselves. Are they comprehensive in that every gene reported to have 
an associated with HL gene is included? Do they include only selected genes which 
have been validated by functional studies, strengthening their association? Are the 
selected genes filtered by ethnicity i.e. the population group in which they were 
discovered or for which the panel is designed for? MiamiOtoGenes as well as 
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OtoSCOPE seem to aim to cater for as many ethnic groups as possible, with OtoSeq 
seemingly targeting populations within the Mediterranean region, seen by the 24 
genes selected for the panel (Shahzad et al., 2013). At the time of selecting a suitable 
panel to use to explore ARNSHL in sub-Saharan Africa, these questions were 
considered, and OtoSCOPE was selected for our study. It was the most 
comprehensive panel at the time and not limiting in the genes included based on the 
ethnicity of the population in which the gene was identified, and MiamiOtoGenes was 
not available. We selected 10 multiplex families from Cameroon presenting with 
ARNSHL and utilized OtoSCOPE (v4) to elucidate the causative variants in 116 known 
HL genes. Subsequent versions of the panel have seen more genes being added with 
the latest available version screening 152 genes. The panel considers both syndromic 
and nonsyndromic presentations of HL and investigates genes which are associated 
with both. Through OtoSCOPE, we were able to resolve 7 families, with 1 of the 10 
failing to enrich adequately. We identified 12 different variants in 6 different genes. We 
also saw 5 novel variants and found that most of the causative variants were found to 
be contributing to the disease as compound heterozygous (Lebeko et al., 2016). We 
demonstrated the utility of a comprehensive panel such as OtoSCOPE, and the 
potential it has to elucidate patients from SSA. The variants identified in our study were 
subsequently screened in our cohort of 80 singleplex cases and were found to not be 
significant in the cohort and unable to resolve any of the cases. With the exception of 
2 previously reported variants identified in family 5 and 7, the other variants were not 
detected in the controls nor the singleplex cases indicating that they might be rare 
variants in the population. We do however recognize that our data was limited by the 
small sample size of families segregating HL, as well as the number of isolated cases 
investigated (Lebeko et al, 2016). Nevertheless, the study illustrated the potential of 
discovering a high proportion of novel mutations in known genes and as well as novel 
genes in population of African ancestry. 
 
Other studies have explored patients of African descent, particularly in the diaspora 
and the ability of these panels to resolve these cases. The findings show a much lower 
detection rate than in our cohor. This could be due to the difference in the inclusion 
criteria as we focused only on familial cases, with highest likelihood of genetic 
aetiology (Lebeko et al, 2016). African Americans and admixed populations from Brazil 
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and the Caribbean islands show the lowest resolution and detection rates across 
platforms and panels where multi-ethnic patients were screened using the same panel. 
The rates vary from 4% using MiamiOtoGenes (Yan et al., 2016) to 26% using 
OtoSCOPE (Sloan-Heggen et al., 2016). It is worth noting that the same filtering and 
annotation pipelines were used for all the populations in the above-mentioned studies 
respectively. This has an influence on the accuracy of the annotation, particularly when 
considering minor allele frequency. This was demonstrated by Shearer et al, that 
ethnicity has a significant influence on the detection but moreover the MAF thresholds 
used (Shearer et al., 2014b). This consideration will need to be applied to data from 
patients of African descent should they make use of these technologies in order to get 
the most accurate results on which variants are likely causative. The results of the two 
above mentioned panels with regards to resolution of African patients with HL, along 
with the presence of two unresolved families in our study (Lebeko et al, 2016) are 
strong evidence to advocate for the use of whole exome sequencing when seeking to 
elucidate causative variants for patients of African descent.  
 
Whole Exome Sequencing in Hearing loss 
The human genome has about 3,5 billion base pairs. Of these, only 1% are known to 
be part of the exome; that is exonic regions of genes which code for regions that make 
up protein products. With Mendelian disorders, it’s most likely an exonic variant that 
will be the causative variant leading to an altered or absent protein. When using WES 
in selected 4 families, 2 resolved by targeted exome sequencing (OtoSCOPE) and two 
that remained unresolved after OtoSCOPE, and  we were able to find a deleterious 
variants in three out of the four families, replicating the result obtained from the 
targeted panel (Lebeko et al, 2016), and discovering a novel c.251delC homozygous 
variant GRXCR2, GRXCR2, a novel HL genes  only reported one in a family from 
Pakistan (Imtiaz et al., 2014). One of the families remained unresolved and could 
indicate the presence of a causative variant in a part of the genome not captured by 
the WES. To our knowledge this is the this is the first study that use of WES to resolve 
HL in SSA. 
When looking at studies that have utilised WES to resolve HL across the world, we 
noticed that there is a higher resolution rate than when using TGE. The rate of 
resolution when analysing large number of samples range from 43% (Choi et al., 2013) 
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to 56% (Bademci et al., 2016). Moreover, when we investigated the rate of gene 
discovery within the studies that have used WES or NGS since 2010, there has been 
a great increase in the discovery of new HL genes and variants (Atik et al., 2015). 
Interestingly, we were not able to find papers where WES was used on Caucasian 
patients. Perhaps this is due to observed genetic saturation in that this population 
group in which the genes have been discovered have no more diversity to offer thus 
we will constantly find the same genes being implicated in HL. This is an additional 
suggestion that novel genes and variants are likely to be found in the largely 
understudied populations of African ancestry.  
The rate of resolution when using WES is much higher than TGE but does not come 
close to completion. This shows that there is still a lot that needs to be done in 
improving WES platforms from capturing, to variant calling, filtering and sorting. 
Improvement of these steps within WES could see an increase in resolution rates  
across all diseases.  
 
 
GRXCR2 in Hearing Loss 
Herein, we report a second variant within GRXCR2 that cases ARNSHL in humans 
with the first being found in a Pakistani family (Imtiaz et al., 2014). Furthermore, this 
novel variant was found to be harboured by another patient within our cohort. 
Exploration of databases has shown one individual of African American descent 
having one copy of this variant, showing that it could potentially be present in some 
patients in the diaspora. This gene has been shown to contribute to HL in a mouse 
model (Avenarius, 2012). These are the only reported consequences of variants in this 
gene. The protein is believed to be involved in the maturation and organization of 
stereocillia bundles of the inner ear hair cells (Avenarius, 2012). The exact mechanism 
is yet to be elucidated. Given the genetic heterogeneity of HI, and the different roles 
that already implicated genes and their proteins play, it is worth exploring the kind of 
interactions these genes and proteins have with one another. This exploration of 
interactions between genes and their proteins was a task we undertook in silico 
(Lebeko et al., 2017). When studying the biological processes these known genes are 
involved in more than 60% is attributed to binding and catalytic activity (Lebeko et al., 
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2017). This gives insight into the intricate and unique roles each gene has in the 
development and maintenance of normal hearing in humans. GRXCR2 has three 
distinct protein binding domains and is postulated to function in a complex or as homo 
or heteromers (Avenarius, 2012). The exact proteins to which GRXCR2 binds have 
yet to be elucidated (Lebeko et al., 2017). Given the morphology of hair cells in the 
absence of GRXCR2, it might be an important chaperone protein that does not itself 
make up the bundles but perhaps deliver to the structural components needed to 
mature and subsequently maintain the integrity of the stereocillia post-partum when 
mechanical stimuli is introduced (Avenarius, 2012). Nonetheless, there is enough 
evidence to show the importance of this gene and its protein in the development and 
maintenance of normal hearing. Our exploration of the entire coding region of 
GRXCR2 did not yield other novel variants which could be contributing to HL in our 
cohort. However, this might not be the case for other African populations affected by 
HL.  
 
Building an African-specific hearing loss Genetic profile 
To date, we have resolved 8/9 families presenting with ARNSHL. Of the 13 variants 
we identified in our families (Lebeko et al, 2016), we were only able to resolve one 
other case from our cohort of 80 singleplexes. The studies indicate the need to recruit 
larger number of families in different regions of the African continent, and to use WES 
to truly capture the nature of the genes and mutations involved in HL in people of 
African ancestry. As more families and patients are recruited, we are able to continue 
the exploration of the most prevalently reported genes. Even though these connexin 
genes are unlikely candidate genes for diagnostics of HL in SSA as already discussed, 
there remains the possibility that there might be other founder variants harboured by 
smaller regions within the population. This allows for the expansion of the frontier of 
new knowledge of HL genes while simultaneously testing and/or fortifying the current 
knowledge. This is one benefit of WES. Another benefit is the ability to retrieve data 
and reanalyse it using different pipelines as well as using the data in other studies not 
related to HL. Indeed, WES databases will benefit from the diversification of data with 
the inclusion of data from a diverse group such as African patients. In building and 
expanding a genetic profile of HL for SSA, there is no doubt that pooled resources 
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would increase the rate at which new regions are covered. The H3Africa initiative is a 
great example of efforts on the continent to increase capacity but also centralize and 
share resources. Such initiatives will see the actualization on biorepositories for 
different regions allowing for retrieval of data as suggested above. Another 
consideration on the road to building an accurate genetic profile is the development of 
a genetic testing algorithm specific to SSA patients with HL. This is especially 
important as we have seen how different considerations need to be made according 
to ethnic groups when calling variants (Shearer et al., 2014b).  
 
Policy and Counselling services implications 
The ultimate goal for these research efforts is to allow for the implementation of early 
detection and screening services. It would be duly beneficial to tackle the HL burden 
in Africa from both environmental and genetic ends. The development of infrastructure 
and an increase in resources should consider the need to accommodate genetic 
screening and testing through the information which will be readily and increasingly 
available as research efforts continue. This includes pre- and postnatal genetic 
screening. For this to become a reality, there needs to be an intention to increase 
training with regards to genetic counsellors on the continent (Gardiner et al, 2018). 
They are an intricate part of the service provided in helping patients and their families 
understand the intention and the limitations of the screening services. In a region 
where communicable diseases and other ailments often take precedent, this might not 
be an easy task, but one that needs to be advocated for. Genetic counsellors play an 
essential role, and with the increase in availability of genetic testing and information, 
one cannot imagine an improved and reformed health care system across the 
continent and not envision their services. This is a service that is already relevant in 
other more commonly known genetic diseases such as down syndrome and sickle cell 
disease. The benefit is alleviation of burden of various diseases through counselling 
and education which ultimately leads to increased quality of life (Abou Tayoun et al., 
2016). 
The availability or provision for prenatal screening might not be warranted as HL is not 
life threatening, but the availability of the service within the first 12 months of life of the 
infant are crucial as they allow for intervention before the development of speech. This 
allows for various options which might restore hearing and allow for speech 
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development in some cases where hearing aids can be employed (progressive 
hearing loss) or cochlear implants can be provided for those who would benefit from 
them (Eppsteiner et al., 2012).   
Conclusions 
In this thesis we have contributed to show that variants in GJB2, GJB6 and GJA1 are 
not significant causes of ARNSHL inpatients from African descents. We have 
subsequently demonstrated the efficacy and accuracy of using both targeted exome 
panel sequencing and WES in clinical setting to resolve HL in a multiplex family from 
Cameroon. Additionally, we have shown that WES is able to detect variants in known 
HL genes and were able to replicate results uncovered through TGE on the 
OtoSCOPE panel. This further strengthens the advocacy of using WES in further 
exploring genetic causes of HL in African patients instead of using available TGE 
panels. In silico tools as well as functional studies demonstrated the pathogenicity of 
our novel c.251delC variant harboured in GRXCR2, as well as provided some insight 
to the possible role of the protein in the stereocilia maturation pathway. Identification 
of the variant in a second patient strengthens the association of the variant and HL as 
well as points towards a possible founder effect which needs to be further investigated. 
Overall therefore, the data strongly supports that genetic studies on families 
segregating HL in sub-Saharan Africa could be the next frontier of HL genetic 
research. This region could prove to be of global importance through the discovery of 
novel variants and genes, and of local relevance by improving HL genetic diagnosis, 
retrospective counselling and testing, as well as prevention and care. This will 
positively impact the future prediction of treatment outcomes in sub-Saharan Africans 
and in people of African descent globally.  
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A 
Appendix 
 
Table 4.A1: Primers used to amplify coding region of GRXCR2 
Primer name Primer sequence (5’ – 3’) Product size (bp) 
GRXCR2-Exon 1 Forward AAC TTC CCA TTT GGT GCA CC 631 
GRXCR2-Exon 1 Reverse TGT ATG GGT GTC AGT TGC TG 
GRXCR2-Exon 2 Forward TTC TCT GCT GTT TCC TGG TAT G 381 
GRXCR2-Exon 2 Reverse CTT GGA GAC CAT TGC TGT AGG 
GRXCR2-Exon 3 Forward CAG CCT TTG CTG TAG TCT AGT 328 
GRXCR2-Exon 3 Reverse AGA AAT AAC TTT AGG GAG GGT AAG A 
 
SDM PCR reaction set up and Parameters 
Table 4.A2: SDM PCR reaction Mix set up 
Component 50ul reaction volumes Final concerntration 
Nuclease free H2O Up to 50uL N/A 
2X KAPA HiFi HotSart ReadyMix 25uL 1X 
10uM Forward primer 1.5 ul 0.3uM 
10uM Reverse Primer 1.5ul 0.3uM 
pCMV6-Entry-GRXCR2 1ul 20ng 
   
 
Table 4.A3.: PCR Cycling Parameters for SDM  
Step Temperature (°C) Duration Cycles 
Initial Denaturation 95 3 min 1 
Denaturation 98 20 sec 15 
Annealing 56 15 sec 
Extension 72 8 min 
Final Extension 72 8 min 1 
 
 
  
B 
Vectors 
 
Figure 4.A1: pCMV6-Entry Vector with GRXCR2 ORF purchased from Origene 
 
 
Figure 4.A2: pEGFP Vector Map: GFP is upstream of MCS 
 
 
Figure 4.A3: pGEM-T Vector- T-overhang allows for easy cloning of PCR products 
  
C 
Buffer compositions 
Boiling blue buffer (10ml) 
Component Volume (ml) 
1.5 M Tris-HCL (pH 6.8) 0.83 
20% SDS 2 
B-mecarptoethanol 1 
Glycerol 2 
H2O 4.166 
Coomassie Brilliant Blue R-250 A pinch amount 
 
PBS (10X) 
Components  Volume/Amount 
NaCl 80g 
KCl 2g 
Na2HPO4 (anhydrous) 14.4g 
KH2PO4(anhydrous) 2.4g 
H20 Add 800ml and mix thoroughly and fill up to 
1L 
Use 1:10 dilution with H2O to get 1X 
 
PBS-TWEEN 
• Dissolved 1ml Tween 20 in 1L 1X PBS 
 
10% Ammonium Persulfate (100ml) 
• Dissolve 1g ammonium persulphate (APS) in 8 ml H2O and adjust volume to 100ml 
 
30% acryl-bisacrylamide mix (100ml) 
• 29g acrylamide  
• 1g N,N’-methylenebisacrylamide 
• 60 ml H2O 
D 
• Heat at 37°C to dissolve the chemicals 
• Adjust volume to 100ml with H2O 
 
12 % Resolving gel (7.5ml) 
Component Volume (ml) 
H2O 2.4 
30% acryl-bisacrylamide mix 3 
1.5M Tris (pH 8.8) 1.95 
10% SDS 0.075 
10% ammonium persulfate 0.075 
TEMED 0.003 
 
5% Stacking gel (2ml) 
Components Volume (ml) 
H2O 1.4 
30% acryl-bisacrylamide mix 0.33 
1.5M Tris (pH 6.8) 0.25 
10% SDS 0.02 
10% ammonium persulfate 0.02 
TEMED 0.002 
 
Running buffer (10X) 
Components Volume/Amount 
SDS 10g 
Tris-base (Trizma) 30g 
Glycine 144g 
H2O Add 800ml to mix thoroughly then fill up to 
1L 
Dilute 1:10 with H2O for 1X 
 
 
E 
Transfer Buffer (10X)  
Components Volume/amount 
Tris 38g 
Glycine 144g 
H2O Add up to 1L 
To make 1X: 
10X Transfer buffer 100ml 
Isopropanol 200ml 
H2O 700ml 
 
Blocking solution 
• 2.5g dried milk in 50ml PBS 
 
Ponceau S Stain Solution (100ml) 
• 2g Ponceau S 
• 30g trichloracetic acid 
• 30g sulfosalicylic acid 
• Dissolve in 80 ml H2O 
Adjust volume to 100ml with H2O 
 
F 
  
